{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T03:56:39Z","timestamp":1794110199024,"version":"4.8.0"},"reference-count":513,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejmech.2025.118213","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T20:03:00Z","timestamp":1761076980000},"page":"118213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"P1","title":["Piperidine-containing drugs and recently studied analogs \u2013 biological activity, mechanism of action and synthetic cascade access to their scaffolds"],"prefix":"10.1016","volume":"302","author":[{"given":"Daniel","family":"\u0141owicki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8072-5877","authenticated-orcid":false,"given":"Piotr","family":"Przybylski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118213_bib1","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41586-020-2650-9","article-title":"Biosynthesis of medicinal tropane alkaloids in yeast","volume":"585","author":"Srinivasan","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.118213_bib2","doi-asserted-by":"crossref","first-page":"12745","DOI":"10.1021\/acs.joc.1c01308","article-title":"Piperidine azasugars bearing lipophilic chains: stereoselective synthesis and biological activity as inhibitors of glucocerebrosidase (GCase)","volume":"86","author":"Clemente","year":"2021","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202200619","article-title":"Synthesis of Uronic acid 1-azasugars as putative inhibitors of \u03b1-Iduronidase, \u03b2-Glucuronidase and Heparanase","volume":"24","author":"Doherty","year":"2023","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejmech.2025.118213_bib4","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1128\/jb.85.6.1295-1299.1963","article-title":"Antimicrobial action of nitrogen-containing steroids","volume":"85","author":"Smith","year":"1963","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.ejmech.2025.118213_bib5","article-title":"Further experiences with nitrogen-containing steroids from aqueous adrenal extracts","volume":"24","author":"Schroeder","year":"1957","journal-title":"Acta Endocrinol."},{"key":"10.1016\/j.ejmech.2025.118213_bib6","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1021\/jm00161a028","article-title":"Azasteroids: structure-activity relationships for inhibition of 5.alpha.-reductase and of androgen receptor binding","volume":"29","author":"Rasmusson","year":"1986","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib7","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s13659-022-00366-9","article-title":"Alkaloids as potential antivirals. A comprehensive review","volume":"13","author":"Faisal","year":"2023","journal-title":"Nat. Prod. Bioprospect."},{"key":"10.1016\/j.ejmech.2025.118213_bib8","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1039\/D2NP00002D","article-title":"Modifications, biological origin and antibacterial activity of naphthalenoid ansamycins","volume":"39","author":"Skrzypczak","year":"2022","journal-title":"Nat. Prod. Rep."},{"key":"10.1016\/j.ejmech.2025.118213_bib9","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.ejmech.2014.07.066","article-title":"Structure and evaluation of antibacterial and antitubercular properties of new basic and heterocyclic 3-formylrifamycin SV derivatives obtained via \u2018click chemistry\u2019 approach","volume":"84","author":"Pyta","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib10","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejmech.2019.01.017","article-title":"Quinolone hybrids and their anti-cancer activities: an overview","volume":"165","author":"Gao","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib11","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejmech.2019.02.009","article-title":"Synthesis, docking and antibacterial studies of more potent amine and hydrazone rifamycin congeners than rifampicin","volume":"167","author":"Pyta","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib12","doi-asserted-by":"crossref","first-page":"11800","DOI":"10.1039\/D3NJ01718D","article-title":"Synthesis and inhibitory activity against MurA and MurZ enzymes of 4H-pyrano[2,3-d]pyrimidine\u20131H-1,2,3-triazole hybrid compounds having piperidine and morpholine rings","volume":"47","author":"Nguyen","year":"2023","journal-title":"New J. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib13","doi-asserted-by":"crossref","first-page":"37731","DOI":"10.1021\/acsomega.3c05883","article-title":"Piperidine: a versatile heterocyclic ring for developing monoamine oxidase inhibitors","volume":"8","author":"Jayan","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2025.118213_bib14","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1021\/acsmedchemlett.1c00549","article-title":"Structure\u2013activity relationship of anti-Mycobacterium abscessus piperidine-4-carboxamides, a new class of NBTI DNA gyrase inhibitors","volume":"13","author":"Beuchel","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118213_bib15","doi-asserted-by":"crossref","first-page":"9860","DOI":"10.1021\/acs.jmedchem.7b01531","article-title":"Azetidine and piperidine carbamates as efficient, covalent inhibitors of monoacylglycerol lipase","volume":"60","author":"Butler","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib16","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1021\/acsmedchemlett.3c00454","article-title":"Identification of spiro[chromene-2,4\u2032-piperidine]s as potent, selective, and Gq-Biased 5-HT2C receptor partial agonists","volume":"15","author":"Jiang","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118213_bib17","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3390\/jcm7070158","article-title":"Tobramycin-linked Efflux Pump inhibitor conjugates synergize fluoroquinolones, rifampicin and Fosfomycin against multidrug-resistant Pseudomonas aeruginosa","volume":"7","author":"Yang","year":"2018","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejmech.2025.118213_bib18","doi-asserted-by":"crossref","first-page":"4496","DOI":"10.1021\/acs.jmedchem.2c00339","article-title":"Antibody\u2013drug conjugates for immunology","volume":"65","author":"Dragovich","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib19","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ejmech.2019.04.034","article-title":"Heterodimeric Rifampicin\u2013Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model","volume":"174","author":"Idowu","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/slct.202303299","article-title":"New Imidazo[4,5-c]pyridine-piperidine hybrids as potential anti-cancer agents and in-silico studies","volume":"9","author":"Rejinthala","year":"2024","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.ejmech.2025.118213_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/slct.202301304","article-title":"Versatile therapeutic values of N-containing heterocycles benzimidazole, piperazine and piperidine hybrids","volume":"8","author":"Zala","year":"2023","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.ejmech.2025.118213_bib22","article-title":"Synthesis and neuroprotective evaluation of substituted indanone\/Benzofuranone and piperidine hybrids","author":"Zeng","year":"2024","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2025.118213_bib23","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1021\/ml500414n","article-title":"Evaluation and synthesis of polar aryl- and heteroaryl spiroazetidine-piperidine acetamides as ghrelin inverse agonists","volume":"6","author":"Orr","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118213_bib24","doi-asserted-by":"crossref","first-page":"5441","DOI":"10.1021\/ja01577a030","article-title":"Correlation of the base strengths of Amines1","volume":"79","author":"Hall","year":"1957","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2025.118213_bib25","unstructured":"Calculation of molecular properties and bioactivity score, (n.d.). https:\/\/www.molinspiration.com\/cgi\/properties (accessed September 18, 2025)."},{"key":"10.1016\/j.ejmech.2025.118213_bib26","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1021\/acsinfecdis.9b00176","article-title":"Specific interactions between rifamycin antibiotics and water influencing ability to overcome natural cell barriers and the range of antibacterial potency","volume":"5","author":"Pyta","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ejmech.2025.118213_bib27","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0168-3659(98)00170-9","article-title":"Tetracycline-HCl-loaded poly(dl-lactide-co-glycolide) microspheres prepared by a spray drying technique: influence of \u03b3-irradiation on radical formation and polymer degradation","volume":"59","author":"Bittner","year":"1999","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.ejmech.2025.118213_bib28","doi-asserted-by":"crossref","first-page":"4455","DOI":"10.1038\/s41467-022-32043-3","article-title":"A long-acting formulation of rifabutin is effective for prevention and treatment of Mycobacterium tuberculosis","volume":"13","author":"Kim","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118213_bib29","author":"Patel"},{"key":"10.1016\/j.ejmech.2025.118213_bib30","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ijpharm.2012.11.028","article-title":"Use of pharmaceutical salts and cocrystals to address the issue of poor solubility","volume":"453","author":"Elder","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejmech.2025.118213_bib31","doi-asserted-by":"crossref","first-page":"6612","DOI":"10.1021\/jm2004283","article-title":"Covalent inhibitors of fatty acid amide hydrolase: a rationale for the activity of piperidine and piperazine aryl ureas","volume":"54","author":"Palermo","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib32","series-title":"Piperidine-Based Drug Discovery","year":"2017"},{"key":"10.1016\/j.ejmech.2025.118213_bib33","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1021\/acschembio.6b00875","article-title":"Deciphering piperidine formation in polyketide-derived indolizidines reveals a thioester reduction, transamination, and unusual imine reduction process","volume":"11","author":"Peng","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.118213_bib34","doi-asserted-by":"crossref","first-page":"972","DOI":"10.2174\/1570179414666170201150701","article-title":"Photochemical reactions: synthesis of six-membered N-heterocycles","volume":"14","author":"Kaur","year":"2017","journal-title":"Curr. Org. Synth."},{"key":"10.1016\/j.ejmech.2025.118213_bib35","first-page":"257","article-title":"Recent trends in synthesis of five- and six-membered heterocycles using dimethyl N-cyanodithioiminocarbonate, Heterocycl","volume":"20","author":"Elgemeie","year":"2014","journal-title":"Commun. Now."},{"key":"10.1016\/j.ejmech.2025.118213_bib36","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1080\/00397911.2020.1776878","article-title":"Synthetic approaches toward piperidine related structures: a review","volume":"50","author":"Bari","year":"2020","journal-title":"Synth. Commun."},{"key":"10.1016\/j.ejmech.2025.118213_bib37","doi-asserted-by":"crossref","first-page":"6620","DOI":"10.1039\/C8OB01271G","article-title":"Strategies for the synthesis of spiropiperidines \u2013 a review of the last 10 years","volume":"16","author":"Griggs","year":"2018","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib38","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2174\/157019308785161701","article-title":"A convenient access to the piperidine ring by cyclization of Allylsilyl substituted N-cyliminium and iminium ions: application to the synthesis of piperidine alkaloids","volume":"5","author":"Remuson","year":"2008","journal-title":"Mini-Reviews Org. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib39","doi-asserted-by":"crossref","first-page":"5493","DOI":"10.1039\/D0OB00918K","article-title":"Stereoselective synthesis of 2,6-disubstituted piperidine alkaloids","volume":"18","author":"Srivastava","year":"2020","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib40","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1021\/jacs.3c11504","article-title":"A general strategy for N-(Hetero)arylpiperidine synthesis using zincke imine intermediates","volume":"146","author":"Selingo","year":"2024","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2025.118213_bib41","series-title":"Alpha-Glucosidase Inhibitors","first-page":"17","article-title":"Chapter two - natural and synthetic sugar mimics","author":"Ghani","year":"2020"},{"key":"10.1016\/j.ejmech.2025.118213_bib42","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1055\/s-0043-1764218","article-title":"Application of chiral piperidine scaffolds in drug design","volume":"5","author":"Chen","year":"2023","journal-title":"Pharm. Fronts"},{"key":"10.1016\/j.ejmech.2025.118213_bib43","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.2174\/1568026623666230406084315","article-title":"Piperidine nucleus as a promising scaffold for alzheimer's disease: current landscape and future perspective","volume":"23","author":"Grover","year":"2023","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.772418","article-title":"Anticancer applications and pharmacological properties of piperidine and piperine: a comprehensive review on molecular mechanisms and therapeutic perspectives","volume":"12","author":"Mitra","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118213_bib45","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ejmech.2018.08.017","article-title":"Recent advancement of piperidine moiety in treatment of cancer- A review","volume":"157","author":"Goel","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib46","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ejmech.2019.04.025","article-title":"Synthetic heterocyclic candidates as promising \u03b1-glucosidase inhibitors: an overview","volume":"176","author":"Dhameja","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib47","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1023\/A:1017505929583","article-title":"Biological activity of 5- and 6-membered azaheterocycles and their synthesis from 5-Aryl-2,3-Dihydrofuran-2,3-diones (Review)","volume":"37","author":"Nekrasov","year":"2001","journal-title":"Chem. Heterocycl. Compd."},{"key":"10.1016\/j.ejmech.2025.118213_bib48","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.3390\/ijms24032937","article-title":"Piperidine derivatives: recent advances in synthesis and pharmacological applications","volume":"24","author":"Frolov","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.118213_bib49","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.2174\/1389201022666210812123815","article-title":"A review of chemistry and pharmacology of piperidine alkaloids of pinus and related genera","volume":"23","author":"Singh","year":"2022","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.ejmech.2025.118213_bib50","first-page":"2826","article-title":"Synthesis of (\u2212)-Paroxetine via enantioselective phase-transfer catalytic monoalkylation of malonamide ester, org","volume":"12","author":"Kim","year":"2010","journal-title":"Letture"},{"key":"10.1016\/j.ejmech.2025.118213_bib51","doi-asserted-by":"crossref","first-page":"8942","DOI":"10.1016\/j.tet.2011.08.079","article-title":"Highly enantioselective organocatalytic cascade reaction for the synthesis of piperidines and oxazolidines","volume":"67","author":"\u010c\u00edhalov\u00e1","year":"2011","journal-title":"Tetrahedron"},{"key":"10.1016\/j.ejmech.2025.118213_bib52","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S0021-9673(01)95038-1","article-title":"Determination of piperine in pepper (Piper nigrum) using high-performance liquid chromatography","volume":"264","author":"Rathnawathie","year":"1983","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.ejmech.2025.118213_bib53","first-page":"1535","article-title":"Isolation of piperdine from Piper nigrum and its antiproliferative activity","volume":"4","author":"Reshmi","year":"2010","journal-title":"JMPR"},{"key":"10.1016\/j.ejmech.2025.118213_bib54","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1600-0773.1945.tb02561.x","article-title":"The occurrence and determination of piperidine in human and animal urine","volume":"1","author":"Euler","year":"1945","journal-title":"Acta Pharmacol. Toxicol."},{"key":"10.1016\/j.ejmech.2025.118213_bib55","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/191201a0","article-title":"Distribution of piperidine in the brain and its possible significance in behaviour","volume":"191","author":"Abood","year":"1961","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.118213_bib56","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.canlet.2014.11.017","article-title":"Piperine inhibits the growth and motility of triple-negative breast cancer cells","volume":"357","author":"Greenshields","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2025.118213_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.772418","article-title":"Anticancer applications and pharmacological properties of piperidine and piperine: a comprehensive review on molecular mechanisms and therapeutic perspectives","volume":"12","author":"Mitra","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118213_bib58","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1212\/WNL.4.1.33","article-title":"Clinical evaluation of Pagitane hydrochloride in parkinsonism","volume":"4","author":"Dow","year":"1954","journal-title":"Neurology"},{"key":"10.1016\/j.ejmech.2025.118213_bib59","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1212\/WNL.4.9.682","article-title":"Treatment of parkinsonism with Pagitane hydrochloride","volume":"4","author":"Zier","year":"1954","journal-title":"Neurology"},{"key":"10.1016\/j.ejmech.2025.118213_bib60","first-page":"64","article-title":"Cycrimine on rat diaphragm","volume":"219","author":"Vedasiromoni","year":"1976","journal-title":"Arch. Int. Pharmacodyn. Ther."},{"key":"10.1016\/j.ejmech.2025.118213_bib61","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3851\/IMP3348","article-title":"In vitro anti-influenza activity of in silico repurposed candidate drug cycrimine","volume":"24","author":"Matejin","year":"2019","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.ejmech.2025.118213_bib62","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/2532764","article-title":"Anti-Parkinson drug biperiden inhibits enzyme acetylcholinesterase","volume":"2017","author":"Kostelnik","year":"2017","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.ejmech.2025.118213_bib64","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1476-5381.1986.tb11123.x","article-title":"Binding and functional profiles of the selective M1 muscarinic receptor antagonists trihexyphenidyl and dicyclomine","volume":"89","author":"Giachetti","year":"1986","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118213_bib65","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3109\/15563659809162581","article-title":"Clinical experience in acute overdosage of diphenidol","volume":"36","author":"Yang","year":"1998","journal-title":"J. Toxicol. Clin. Toxicol."},{"key":"10.1016\/j.ejmech.2025.118213_bib66","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s12024-015-9709-1","article-title":"Fatal diphenidol poisoning: a case report and a retrospective study of 16 cases","volume":"11","author":"Zhang","year":"2015","journal-title":"Forensic Sci. Med. Pathol."},{"key":"10.1016\/j.ejmech.2025.118213_bib67","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1093\/jat\/bkaa160","article-title":"Application of a validated UPLC\u2013MS-MS method for the determination of diphenidol in biological samples in 15 authentic lethal cases","volume":"45","author":"Yang","year":"2021","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.ejmech.2025.118213_bib68","series-title":"Withdrawal of Approval of 92 New Drug Applications and 49 Abbreviated New Drug Applications","first-page":"24905","year":"2004"},{"key":"10.1016\/j.ejmech.2025.118213_bib69","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/chir.530030207","article-title":"Stereoselectivity of (R)- and (S)-hexahydro-difenidol binding to neuroblastoma M1, cardiac M2, pancreatic M3, and striatum M4 muscarinic receptors","volume":"3","author":"Waelbroeck","year":"1991","journal-title":"Chirality"},{"key":"10.1016\/j.ejmech.2025.118213_bib70","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/anie.198001841","article-title":"3-Phenylpropylamines, A new class of systemic fungicides","volume":"19","author":"Himmele","year":"1980","journal-title":"Angew. Chem., Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2025.118213_bib71","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ps.2780150311","article-title":"Chemical structure-fungicidal activity relationships in substituted morpholines","volume":"15","author":"Pommer","year":"1984","journal-title":"Pestic. Sci."},{"key":"10.1016\/j.ejmech.2025.118213_bib72","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1128\/AAC.35.8.1532","article-title":"Physiological effects of fenpropimorph on wild-type Saccharomyces cerevisiae and fenpropimorph-resistant mutants","volume":"35","author":"Lorenz","year":"1991","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2025.118213_bib73","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S0031-9422(00)84762-7","article-title":"Inhibition of sterol \u03948 \u2192 \u03947-isomerase and \u039414-reductase by fenpropimorph tridemorph and fenpropidin in cell-free enzyme systems from Saccharomyces cerevisiae","volume":"26","author":"Baloch","year":"1987","journal-title":"Phytochemistry"},{"key":"10.1016\/j.ejmech.2025.118213_bib74","first-page":"16984","article-title":"Screening for a fenpropidin enantiomer with high activity and low toxicity","volume":"71","author":"Li","year":"2023","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib75","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/j.1476-5381.2011.01286.x","article-title":"The histamine H3 receptor: from discovery to clinical trials with pitolisant","volume":"163","author":"Schwartz","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118213_bib76","year":"2020"},{"key":"10.1016\/j.ejmech.2025.118213_bib78","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1007\/s40265-016-0620-1","article-title":"Pitolisant: first global approval","volume":"76","author":"Syed","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.118213_bib79","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1093\/ajhp\/55.2.104","article-title":"Raloxifene approval ushers in new drug class for osteoporosis. Estrogen-receptor effects vary by tissue type","volume":"55","year":"1998","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.ejmech.2025.118213_bib80","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1001\/jama.281.23.2189","article-title":"The effect of raloxifene on risk of breast cancer in postmenopausal WomenResults from the MORE randomized trial","volume":"281","author":"Cummings","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.ejmech.2025.118213_bib81","doi-asserted-by":"crossref","first-page":"721","DOI":"10.2165\/00002018-200528080-00006","article-title":"Benefit-risk assessment of raloxifene in postmenopausal osteoporosis","volume":"28","author":"Cranney","year":"2005","journal-title":"Drug Saf."},{"key":"10.1016\/j.ejmech.2025.118213_bib82","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1124\/dmd.121.000549","article-title":"The inactivation of human aldehyde oxidase 1 by hydrogen peroxide and superoxide","volume":"49","author":"Garrido","year":"2021","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejmech.2025.118213_bib83","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jsbmb.2010.06.012","article-title":"Metabolic impact of estrogen signalling through ERalpha and ERbeta","volume":"122","author":"Foryst-Ludwig","year":"2010","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.ejmech.2025.118213_bib84","doi-asserted-by":"crossref","first-page":"13025","DOI":"10.1021\/acs.jmedchem.1c01125","article-title":"Interrogating the inhibition mechanisms of human aldehyde oxidase by X-ray crystallography and NMR spectroscopy: the raloxifene case","volume":"64","author":"Mota","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib85","first-page":"3205","article-title":"Biomarkers for systemic therapy in metastatic breast cancer: ASCO guideline update","volume":"40","author":"Henry","year":"2022","journal-title":"J. Clin. Orthod."},{"key":"10.1016\/j.ejmech.2025.118213_bib86","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.72512","article-title":"Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in ESR1 mutant breast cancer cells","volume":"11","author":"Hosfield","year":"2022","journal-title":"eLife"},{"key":"10.1016\/j.ejmech.2025.118213_bib87","doi-asserted-by":"crossref","first-page":"7390","DOI":"10.1021\/acs.jmedchem.4c03065","article-title":"From bones to bugs: structure-based development of raloxifene-derived pathoblockers that inhibit pyocyanin production in Pseudomonas aeruginosa","volume":"68","author":"Thiemann","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib88","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1158\/1940-6207.CAPR-15-0109","article-title":"Clinical trial of acolbifene in premenopausal women at high risk for breast cancer","volume":"8","author":"Fabian","year":"2015","journal-title":"Cancer Prev. Res."},{"key":"10.1016\/j.ejmech.2025.118213_bib89","first-page":"165","article-title":"Synthesis and structure\u2013activity relationships of analogs of EM-652 (acolbifene), a pure selective estrogen receptor modulator. Study of nitrogen substitution, Enzyme Inhib","volume":"20","author":"Gauthier","year":"2005","journal-title":"Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib90","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1001\/archderm.1955.01540300050013","article-title":"Evaluation of a new topical anesthetic, dyclonine hydrochloride","volume":"71","author":"Shelmire","year":"1955","journal-title":"AMA Arch. Derm."},{"key":"10.1016\/j.ejmech.2025.118213_bib91","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/00000542-195609000-00002","article-title":"Dyclonine - a new local anesthetic agent: clinical evaluation","volume":"17","author":"Harris","year":"1956","journal-title":"Anesthesiology"},{"key":"10.1016\/j.ejmech.2025.118213_bib92","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1080\/00325481.1956.11708352","article-title":"Dyclonine hydrochloride: a new topical antipruritic agent","volume":"19","author":"Morginson","year":"1956","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.ejmech.2025.118213_bib93","article-title":"Therapeutic inhibition of keratinocyte TRPV3 sensory channel by local anesthetic dyclonine","volume":"10","author":"Liu","year":"2021","journal-title":"eLife"},{"key":"10.1016\/j.ejmech.2025.118213_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.ceca.2022.102617","article-title":"Dyclonine inhibition of TRPV3: from functional discovery to structural insight","volume":"105","author":"Wang","year":"2022","journal-title":"Cell Calcium"},{"key":"10.1016\/j.ejmech.2025.118213_bib95","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1038\/s41467-022-30537-8","article-title":"Structural mechanism of TRPV3 channel inhibition by the anesthetic dyclonine","volume":"13","author":"Neuberger","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118213_bib96","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s40265-018-1028-x","article-title":"Dacomitinib: first global approval","volume":"78","author":"Shirley","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.118213_bib97","doi-asserted-by":"crossref","first-page":"5105","DOI":"10.1007\/s11033-023-08432-2","article-title":"An association of epidermal growth factor receptor mutation subtypes with prognostic prediction and site-specific recurrence in advanced stage lung cancer patients","volume":"50","author":"Joshi","year":"2023","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.ejmech.2025.118213_bib98","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2022-001492","article-title":"Differential clinicopathological features, treatments and outcomes in patients with Exon 19 deletion and Exon 21 L858R EGFR mutation-positive adenocarcinoma non-small-cell lung cancer","volume":"10","author":"Batra","year":"2023","journal-title":"BMJ Open Respir. Res."},{"key":"10.1016\/j.ejmech.2025.118213_bib99","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.str.2012.11.014","article-title":"Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition","volume":"21","author":"Gajiwala","year":"2013","journal-title":"Structure"},{"key":"10.1016\/j.ejmech.2025.118213_bib100","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s40265-024-02129-x","article-title":"Arimoclomol: first approval","volume":"85","author":"Keam","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.118213_bib101","article-title":"Long-term efficacy and safety of arimoclomol in Niemann-Pick disease type C: final results of the phase 2\/3 NPC-002 48-month open-label extension trial","volume":"145","year":"2025","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ejmech.2025.118213_bib102","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1007\/s10072-025-08062-5","article-title":"Safety and efficacy of arimoclomol in amyotrophic lateral sclerosis: a systematic review and meta-analysis","volume":"46","author":"Masood","year":"2025","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.ejmech.2025.118213_bib103","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1161\/01.CIR.45.3.571","article-title":"Combined therapy with vasodilator drugs and beta-adrenergic blockade in hypertension","volume":"45","author":"Gottlieb","year":"1972","journal-title":"Circulation"},{"key":"10.1016\/j.ejmech.2025.118213_bib104","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1007\/s13555-024-01197-x","article-title":"Evaluation of the safety and effectiveness of oral minoxidil in children: a systematic review","volume":"14","author":"Williams","year":"2024","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.ejmech.2025.118213_bib105","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1524-6175.2004.03585.x","article-title":"Minoxidil: an underused vasodilator for resistant or severe hypertension","volume":"6","author":"Sica","year":"2004","journal-title":"J. Clin. Hypertens."},{"key":"10.1016\/j.ejmech.2025.118213_bib106","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s13671-023-00414-8","article-title":"Oral minoxidil therapy in hair loss: where do we Stand?","volume":"12","author":"Alhetheli","year":"2023","journal-title":"Curr. Derm. Rep."},{"key":"10.1016\/j.ejmech.2025.118213_bib107","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jaad.2020.06.1009","article-title":"Oral minoxidil treatment for hair loss: a review of efficacy and safety","volume":"84","author":"Randolph","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.ejmech.2025.118213_bib108","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/bja\/39.10.775","article-title":"The neuromuscular blocking properties of a new steroid compound, pancuronium bromide: a Pilot Study in Man","volume":"39","author":"Baird","year":"1967","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.ejmech.2025.118213_bib109","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1097\/00000542-200305000-00006","article-title":"Potentiation of mivacurium blockade by low dose of pancuronium: a pharmacokinetic study","volume":"98","author":"Motamed","year":"2003","journal-title":"Anesthesiology"},{"key":"10.1016\/j.ejmech.2025.118213_bib110","doi-asserted-by":"crossref","first-page":"49S","DOI":"10.1093\/bja\/52.suppl_1.49S","article-title":"First clinical Experiences with ORG NC 45","volume":"52","author":"Crul","year":"1980","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.ejmech.2025.118213_bib111","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/j.1365-2044.1983.tb12023.x","article-title":"An evaluation of Org NC 45 (vecuronium) in paediatric anaesthesia","volume":"38","author":"Ferres","year":"1983","journal-title":"Anaesthesia"},{"key":"10.1016\/j.ejmech.2025.118213_bib112","series-title":"Vecuronium, in: StatPearls","author":"Ramzy","year":"2024"},{"key":"10.1016\/j.ejmech.2025.118213_bib113","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jclinane.2017.06.006","article-title":"Sugammadex efficacy for reversal of rocuronium- and vecuronium-induced neuromuscular blockade: a pooled analysis of 26 studies","volume":"41","author":"Herring","year":"2017","journal-title":"J. Clin. Anesth."},{"key":"10.1016\/j.ejmech.2025.118213_bib114","doi-asserted-by":"crossref","first-page":"887","DOI":"10.2165\/00003495-199958050-00011","article-title":"Rapacuronium bromide","volume":"58","author":"Onrust","year":"1999","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.118213_bib115","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1213\/00000539-200210000-00079","article-title":"Further comments on the withdrawal of Rapacuronium","volume":"95","author":"Sosis","year":"2002","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.ejmech.2025.118213_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2019.127336","article-title":"Axial chirality inversion at a spiro carbon leads to efficient synthesis of polyimine macrocycle","volume":"1202","author":"Zgorzelak","year":"2020","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.ejmech.2025.118213_bib117","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S1005-9040(08)60092-6","article-title":"Chiral separation of spiro-compounds and determination configuration","volume":"24","author":"Liang","year":"2008","journal-title":"Chem. Res. Chin. Univ."},{"key":"10.1016\/j.ejmech.2025.118213_bib118","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1749-6632.1955.tb42456.x","article-title":"Treatment of reserpine-induced depression with a new analeptic: phenidylate","volume":"61","author":"Ferguson","year":"1955","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ejmech.2025.118213_bib119","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jaac.2024.02.008","article-title":"AACAP endorses the Inclusion of methylphenidate in the WHO model lists of essential medicines","volume":"63","author":"Cortese","year":"2024","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.ejmech.2025.118213_bib120","doi-asserted-by":"crossref","first-page":"8","DOI":"10.2165\/00042310-199913030-00004","article-title":"Methylphenidate still first line, but combination treatment often required in adults with attention deficit hyperactivity disorder","volume":"13","year":"1999","journal-title":"Drugs Ther. Perspect."},{"key":"10.1016\/j.ejmech.2025.118213_bib121","article-title":"ADHD: methylphenidate should be first line drug treatment in children, review confirms","volume":"362","author":"Iacobucci","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.ejmech.2025.118213_bib122","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2165\/00023210-200620090-00002","article-title":"Methylphenidate and its isomers","volume":"20","author":"Heal","year":"2006","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejmech.2025.118213_bib123","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1089\/cap.2007.0015","article-title":"Efficacy and safety of extended-release Dexmethylphenidate compared with d,l-methylphenidate and placebo in the treatment of children with attention-deficit\/hyperactivity disorder: a 12-Hour Laboratory classroom study","volume":"18","author":"Muniz","year":"2008","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.ejmech.2025.118213_bib124","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1089\/cap.2006.16.239","article-title":"Efficacy and Duration of effect of extended-release Dexmethylphenidate versus placebo in Schoolchildren with attention-deficit\/hyperactivity disorder","volume":"16","author":"Silva","year":"2006","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.ejmech.2025.118213_bib125","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1001\/jamacardio.2017.1320","article-title":"Efficacy of flecainide in the treatment of Catecholaminergic Polymorphic Ventricular tachycardia: a randomized clinical trial","volume":"2","author":"Kannankeril","year":"2017","journal-title":"JAMA Cardiology"},{"key":"10.1016\/j.ejmech.2025.118213_bib126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-198529010-00001","article-title":"Flecainide","volume":"29","author":"Holmes","year":"1985","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.118213_bib127","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/clpt.1980.65","article-title":"Antiarrhythmic effects of flecainide","volume":"27","author":"Somani","year":"1980","journal-title":"Clin. Pharm. Therap."},{"key":"10.1016\/j.ejmech.2025.118213_bib129","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/0022-2828(82)90231-0","article-title":"Calcium channel blockade by perhexiline maleate and its M1 metabolite","volume":"14","author":"Horowitz","year":"1982","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.ejmech.2025.118213_bib130","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejcnurse.2006.01.001","article-title":"Metabolic therapeutics in Angina Pectoris: History revisited with perhexiline","volume":"5","author":"Inglis","year":"2006","journal-title":"Eur. J. Cardiovasc. Nurs."},{"key":"10.1016\/j.ejmech.2025.118213_bib131","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0006-2952(96)00204-3","article-title":"Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone","volume":"52","author":"Kennedy","year":"1996","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118213_bib132","first-page":"76","article-title":"Perhexiline, Cardiovasc","volume":"25","author":"Ashrafian","year":"2007","journal-title":"Drug Rev."},{"key":"10.1016\/j.ejmech.2025.118213_bib133","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1158\/1535-7163.MCT-19-1047","article-title":"Perhexiline demonstrates FYN-mediated antitumor activity in Glioblastoma","volume":"19","author":"Kant","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejmech.2025.118213_bib134","doi-asserted-by":"crossref","DOI":"10.1038\/srep18144","article-title":"Perhexiline maleate enhances antitumor efficacy of cisplatin in neuroblastoma by inducing over-expression of NDM29 ncRNA","volume":"5","author":"Vella","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2025.118213_bib135","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1532-5415.1957.tb00077.x","article-title":"Pipradrol (meratran) in Institutionalized Geriatric patients\u2020","volume":"5","author":"LeHew","year":"1957","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.ejmech.2025.118213_bib136","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/j.1552-4604.1974.tb02302.x","article-title":"Pipradrol in mild depression: a controlled study","volume":"14","author":"Rickels","year":"1974","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118213_bib137","first-page":"55","article-title":"The use of pipradrol in the problems of obesity","volume":"170","author":"Perlstein","year":"1957","journal-title":"Int. Rec. Med. Gen. Pract. Clin."},{"key":"10.1016\/j.ejmech.2025.118213_bib138","first-page":"2336","article-title":"Alpha-(2-piperidyl) benzhydrol hydrochloride (pipradrol) as an adjunct in the dietary management of obesity","volume":"55","author":"Gelvin","year":"1955","journal-title":"N. Y. State J. Med."},{"key":"10.1016\/j.ejmech.2025.118213_bib139","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.4269\/ajtmh.1980.29.1131","article-title":"Chemosuppressive field trials in Thailand: IV. The suppression of Plasmodium falciparum and Plasmodium vivax Parasitemias by mefloquine (WR 142,490, a 4-Quinolinemethanol)","volume":"29","author":"Pearlman","year":"1980","journal-title":"Am. J. Trop. Med."},{"key":"10.1016\/j.ejmech.2025.118213_bib140","doi-asserted-by":"crossref","first-page":"648","DOI":"10.4269\/ajtmh.1994.51.648","article-title":"A strong association between mefloquine and Halofantrine resistance and Amplification, Overexpression, and mutation in the P-glycoprotein gene homolog (pfmdr) of Plasmodium falciparum in vitro","volume":"51","author":"Peel","year":"1994","journal-title":"Am. J. Trop. Med."},{"key":"10.1016\/j.ejmech.2025.118213_bib141","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1093\/cid\/ciw121","article-title":"Efficacy of Artesunate-mefloquine for chloroquine-resistant Plasmodium vivax malaria in Malaysia: an open-label, randomized, controlled trial","volume":"62","author":"Grigg","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejmech.2025.118213_bib142","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1128\/AAC.35.11.2238","article-title":"Crystal structure and molecular structure of mefloquine methylsulfonate monohydrate: implications for a malaria receptor, Antimicrob","volume":"35","author":"Karle","year":"1991","journal-title":"Agents Chemother."},{"key":"10.1016\/j.ejmech.2025.118213_bib143","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1107\/S160057671401303X","article-title":"Elucidating the crystal structure of the antimalarial drug (\u00b1)-mefloquine hydrochloride: a tetragonal hydrated species","volume":"47","author":"Mendes do Prado","year":"2014","journal-title":"J. Appl. Cryst."},{"key":"10.1016\/j.ejmech.2025.118213_bib144","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1128\/AAC.46.5.1529-1534.2002","article-title":"Crystal structure of (\u2212)-Mefloquine hydrochloride reveals consistency of configuration with biological activity","volume":"46","author":"Karle","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2025.118213_bib145","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1007\/s40265-015-0477-8","article-title":"Cobimetinib: first global approval","volume":"75","author":"Garnock-Jones","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.118213_bib146","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1517\/14656566.2016.1168806","article-title":"Cobimetinib and vemurafenib for the treatment of melanoma","volume":"17","author":"Boespflug","year":"2016","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.ejmech.2025.118213_bib147","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.bbrc.2019.12.032","article-title":"MEK inhibition by cobimetinib suppresses hepatocellular carcinoma and angiogenesis in vitro and in vivo","volume":"523","author":"Tong","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2025.118213_bib148","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.bbrc.2020.06.082","article-title":"Targeted MEK inhibition by cobimetinib enhances doxorubicin's efficacy in osteosarcoma models","volume":"529","author":"Ma","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2025.118213_bib149","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2025.118213_bib150","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2020-0292","article-title":"A phase Ib study to evaluate the MEK inhibitor cobimetinib in combination with the ERK1\/2 inhibitor GDC\u20100994 in patients with advanced solid tumors","volume":"25","author":"Weekes","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.ejmech.2025.118213_bib151","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1021\/ml300049d","article-title":"Novel carboxamide-based allosteric MEK inhibitors: discovery and optimization efforts toward XL518 (GDC-0973)","volume":"3","author":"Rice","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118213_bib152","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1021\/jm5018237","article-title":"Niraparib: a poly(ADP-ribose) polymerase (PARP) inhibitor for the treatment of tumors with Defective homologous recombination","volume":"58","author":"Jones","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib153","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00280-017-3512-5","article-title":"The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer","volume":"81","author":"Moore","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118213_bib154","doi-asserted-by":"crossref","first-page":"9557","DOI":"10.1007\/s00253-019-10148-y","article-title":"Autophagy suppression enhances DNA damage and cell death upon treatment with PARP inhibitor Niraparib in laryngeal squamous cell carcinoma","volume":"103","author":"Ji","year":"2019","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.ejmech.2025.118213_bib155","doi-asserted-by":"crossref","first-page":"37080","DOI":"10.18632\/oncotarget.26354","article-title":"A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models","volume":"9","author":"Sun","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2025.118213_bib156","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1111\/cas.13721","article-title":"Phase II study of ceritinib in alectinib-pretreated patients with anaplastic lymphoma kinase-rearranged metastatic non-small-cell lung cancer in Japan: ASCEND-9","volume":"109","author":"Hida","year":"2018","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejmech.2025.118213_bib157","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.2217\/fon-2020-1119","article-title":"ALTA-2: phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib","volume":"17","author":"Kim","year":"2021","journal-title":"Future Oncol."},{"key":"10.1016\/j.ejmech.2025.118213_bib158","doi-asserted-by":"crossref","first-page":"8201","DOI":"10.2147\/OTT.S173008","article-title":"Afatinib reverses ceritinib resistance (CR) in ALK\/ROS1-positive non-small-cell lung cancer cell (NSCLC) via suppression of NRG1 pathway","volume":"11","author":"Chen","year":"2018","journal-title":"OTT"},{"key":"10.1016\/j.ejmech.2025.118213_bib159","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1158\/1078-0432.CCR-21-1838","article-title":"ASCEND-7: efficacy and safety of ceritinib treatment in patients with ALK-positive non\u2013small cell lung cancer metastatic to the brain and\/or Leptomeninges","volume":"28","author":"Chow","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118213_bib160","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1158\/2159-8290.CD-13-0846","article-title":"The ALK inhibitor ceritinib Overcomes crizotinib resistance in non\u2013small cell lung cancer","volume":"4","author":"Friboulet","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2025.118213_bib161","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1192\/bjp.147.3.306","article-title":"A double-blind out-patient trial of Indalpine vs Mianserin","volume":"147","author":"Naylor","year":"1985","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.ejmech.2025.118213_bib162","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/026988119701100303","article-title":"Influence of anxiolytic drugs on the effects of specific serotonin reuptake inhibitors in the forced swimming test in mice","volume":"11","author":"Da-Rocha","year":"1997","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.ejmech.2025.118213_bib163","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1159\/000118243","article-title":"Plasma 3,4-Dihydroxyphenylethyleneglycol and therapeutic Response to Maprotiline and Indalpine in major depression","volume":"15","author":"L\u00f4o","year":"2008","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.ejmech.2025.118213_bib164","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/00007691-200008000-00006","article-title":"Use of the mesoridazine\/thioridazine Ratio as a marker for CYP2D6 enzyme activity","volume":"22","author":"Llerena","year":"2000","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.ejmech.2025.118213_bib165","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1176\/ajp.130.6.689","article-title":"Mesoridazine versus Chlorpromazine in acute schizophrenia: a double-blind investigation","volume":"130","author":"Hamid","year":"1973","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ejmech.2025.118213_bib166","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/0010-440X(78)90083-4","article-title":"Treatment with mesoridazine and thioridazine in chronic schizophrenia: I. Assessment of clinical and electrophysiologic responses in refractory hallucinating schizophrenics","volume":"19","author":"Gardos","year":"1978","journal-title":"Compr. Psychiatry"},{"key":"10.1016\/j.ejmech.2025.118213_bib167","first-page":"484","article-title":"An open study of mesoridazine (Serentil) in chronic schizophrenics","volume":"36","author":"Aguilar","year":"1975","journal-title":"Dis. Nerv. Syst."},{"key":"10.1016\/j.ejmech.2025.118213_bib168","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/BF00613621","article-title":"Serum concentration and protein binding of thioridazine and its metabolites in patients with chronic alcoholism","volume":"23","author":"Axelsson","year":"1982","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118213_bib169","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jagp.2017.01.076","article-title":"Antipsychotic Use and physical Morbidity in Parkinson disease","volume":"25","author":"Weintraub","year":"2017","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.ejmech.2025.118213_bib170","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1017\/S1041610297004560","article-title":"Clinical experience with risperidone, haloperidol, and thioridazine for dementia-associated behavioral disturbances","volume":"9","author":"Frenchman","year":"1997","journal-title":"Int. Psychogeriatr."},{"key":"10.1016\/j.ejmech.2025.118213_bib171","first-page":"1227","article-title":"Outcome of patients after market withdrawal of thioridazine: a retrospective analysis in a nationwide cohort, Pharmacoepidemiol","volume":"21","author":"Purhonen","year":"2012","journal-title":"Drug Saf."},{"key":"10.1016\/j.ejmech.2025.118213_bib172","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/nchembio.1895","article-title":"Structural insights into xenobiotic and inhibitor binding to human aldehyde oxidase","volume":"11","author":"Coelho","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.118213_bib173","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1021\/acs.jmedchem.8b00350","article-title":"Structures of ebola virus glycoprotein complexes with tricyclic antidepressant and antipsychotic drugs","volume":"61","author":"Zhao","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib174","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116556","article-title":"Seven-membered N-heterocycles as approved drugs and promising leads in medicinal chemistry as well as the metal-free domino access to their scaffolds","volume":"275","author":"Le\u015bniewska","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib175","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/pgmj.67.785.227","article-title":"Parkinson and his disease revisited","volume":"67","author":"James","year":"1991","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.ejmech.2025.118213_bib176","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1192\/bjp.112.487.633","article-title":"A controlled trial of anti-Parkinson drugs in drug-induced parkinsonism","volume":"112","author":"Ekdawi","year":"1966","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.ejmech.2025.118213_bib177","doi-asserted-by":"crossref","DOI":"10.1172\/JCI161142","article-title":"Metixene is an incomplete autophagy inducer in preclinical models of metastatic cancer and brain metastases","volume":"133","author":"Fares","year":"2023","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejmech.2025.118213_bib178","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1517\/17425255.1.3.527","article-title":"Donepezil: a review","volume":"1","author":"Seltzer","year":"2005","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.ejmech.2025.118213_bib179","first-page":"1642","article-title":"First donepezil transdermal Patch approved for Alzheimer disease","volume":"327","author":"Larkin","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.ejmech.2025.118213_bib180","doi-asserted-by":"crossref","first-page":"10282","DOI":"10.1021\/jm300871x","article-title":"Structures of human acetylcholinesterase in complex with pharmacologically important ligands","volume":"55","author":"Cheung","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib181","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0920-9964(01)00329-2","article-title":"The effect of melperone, an atypical antipsychotic drug, on cognitive function in schizophrenia","volume":"59","author":"Sumiyoshi","year":"2003","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.ejmech.2025.118213_bib182","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/schbul\/sbac013","article-title":"Efficacy and safety of Roluperidone for the treatment of negative symptoms of schizophrenia","volume":"48","author":"Davidson","year":"2022","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.ejmech.2025.118213_bib183","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/jama.1997.03540290022010","article-title":"From the food and drug administration","volume":"277","author":"Nightingale","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.ejmech.2025.118213_bib184","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/ajhp\/54.4.342","volume":"54","year":"1997","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.ejmech.2025.118213_bib185","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1158\/1078-0432.CCR-12-0411","article-title":"Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and drug administration drug approval summary","volume":"18","author":"Thornton","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118213_bib186","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta23080","article-title":"Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model","volume":"23","author":"Tappenden","year":"2019","journal-title":"Health Technol. Assess."},{"key":"10.1016\/j.ejmech.2025.118213_bib187","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.schres.2006.09.012","article-title":"Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial","volume":"90","author":"Kane","year":"2007","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.ejmech.2025.118213_bib188","first-page":"825","volume":"151","year":"1994","journal-title":"Aust. J. Pharm."},{"key":"10.1016\/j.ejmech.2025.118213_bib189","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nature25758","article-title":"Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone","volume":"555","author":"Wang","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.118213_bib190","first-page":"606","article-title":"Iloperidone (Fanapt): an FDA-approved treatment option for schizophrenia","volume":"34","author":"Montes","year":"2009","journal-title":"P T"},{"key":"10.1016\/j.ejmech.2025.118213_bib191","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2147\/CE.S114094","article-title":"Iloperidone in the treatment of schizophrenia: an evidence-based review of its place in therapy","volume":"11","author":"Tonin","year":"2016","journal-title":"Core Evid."},{"key":"10.1016\/j.ejmech.2025.118213_bib192","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/WNL.49.6.1485","article-title":"The Naratriptan S2WA3003 Study Group\u2217, Naratriptan is effective and well tolerated in the acute treatment of migraine","volume":"49","author":"Mathew","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.ejmech.2025.118213_bib193","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1093\/ajhp\/55.7.638a","article-title":"Oral naratriptan approved for migraine attacks","volume":"55","author":"Kaiser\u2019s","year":"1998","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.ejmech.2025.118213_bib194","first-page":"SE23","article-title":"Current Concepts of phenylpiperidine derivatives use in the treatment of acute and chronic pain","volume":"20","author":"Elbaridi","year":"2017","journal-title":"Pain Physician"},{"key":"10.1016\/j.ejmech.2025.118213_bib195","series-title":"Opioids: Pharmacology, Abuse, and Addiction","first-page":"149","article-title":"Opioids effects and classification","author":"Cruz","year":"2022"},{"key":"10.1016\/j.ejmech.2025.118213_bib196","doi-asserted-by":"crossref","first-page":"697","DOI":"10.2174\/156802606776894447","article-title":"Recent advances in the development of NR2B subtype-selective NMDA receptor antagonists","volume":"6","author":"Layton","year":"2006","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib197","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/00004714-199808000-00004","article-title":"Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline","volume":"18","author":"Waldinger","year":"1998","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.ejmech.2025.118213_bib198","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1177\/106002809302701012","article-title":"Paroxetine: a selective serotonin reuptake inhibiting antidepressant","volume":"27","author":"Caley","year":"1993","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.ejmech.2025.118213_bib199","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41594-018-0026-8","article-title":"Structural basis for recognition of diverse antidepressants by the human serotonin transporter","volume":"25","author":"Coleman","year":"2018","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ejmech.2025.118213_bib200","doi-asserted-by":"crossref","first-page":"628","DOI":"10.7326\/0003-4819-10-5-628","article-title":"Control of the tobacco habit","volume":"10","author":"Dorsey","year":"1936","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ejmech.2025.118213_bib201","first-page":"1","article-title":"Lobeline for smoking cessation","author":"Stead","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejmech.2025.118213_bib202","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2174\/157018012798193017","article-title":"Lobeline docking on AChBP and nicotinic receptors: Discriminating importance of the pocket geometry and of the ligand configuration","volume":"9","author":"Colas","year":"2012","journal-title":"Lett. Drug Des. Discov."},{"key":"10.1016\/j.ejmech.2025.118213_bib203","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1007\/s00213-014-3472-y","article-title":"The effects of lobeline on nicotine withdrawal-induced depression-like behavior in mice","volume":"231","author":"Roni","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejmech.2025.118213_bib204","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1074\/jbc.M117.815316","article-title":"An allosteric binding site of the \u03b17 nicotinic acetylcholine receptor revealed in a humanized acetylcholine-binding protein","volume":"293","author":"Delbart","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib205","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1016\/j.bmc.2016.07.024","article-title":"Steric structure\u2013activity relationship of cyproheptadine derivatives as inhibitors of histone methyltransferase Set7\/9","volume":"24","author":"Fujiwara","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib207","first-page":"32","article-title":"Treatment of pruritis in allergic dermatoses: an evaluation of the relative efficacy of cyproheptadine and hydroxyzine","volume":"19","author":"Baraf","year":"1976","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"10.1016\/j.ejmech.2025.118213_bib208","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/jcpt.12796","article-title":"An 11-year retrospective review of cyproheptadine use in serotonin syndrome cases reported to the California Poison Control System","volume":"44","author":"Nguyen","year":"2019","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.ejmech.2025.118213_bib209","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1212\/WNL.34.3.304","article-title":"The calcium antagonist properties of cyproheptadine","volume":"34","author":"Peroutka","year":"1984","journal-title":"Neurology"},{"key":"10.1016\/j.ejmech.2025.118213_bib210","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/ajg.2017.194","article-title":"Prophylactic therapy of cyclic vomiting syndrome in children: comparison of Amitriptyline and cyproheptadine: a randomized clinical trial","volume":"113","author":"Badihian","year":"2018","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.ejmech.2025.118213_bib211","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.appet.2019.02.012","article-title":"Use of cyproheptadine to stimulate appetite and body weight gain: a systematic review","volume":"137","author":"Harrison","year":"2019","journal-title":"Appetite"},{"key":"10.1016\/j.ejmech.2025.118213_bib212","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/MPG.0000000000000964","article-title":"Cyproheptadine use in children with functional gastrointestinal disorders","volume":"62","author":"Madani","year":"2016","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.ejmech.2025.118213_bib213","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1021\/acs.jmedchem.5b01732","article-title":"Identification of cyproheptadine as an inhibitor of SET domain containing lysine methyltransferase 7\/9 (Set7\/9) that regulates estrogen-dependent transcription","volume":"59","author":"Takemoto","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib214","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1177\/039463201202500125","article-title":"A comparative study of Loratadine Syrup and cyproheptadine HCL solution for treating Perennial allergic rhinitis in Taiwanese children aged 2\u201312 Years","volume":"25","author":"Wu","year":"2012","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118213_bib215","doi-asserted-by":"crossref","first-page":"477","DOI":"10.21608\/bfsa.2021.207175","article-title":"The clinical efficacy of desloratadine, a non-sedating antihistamine, in the management of allergic conditions: a review of the evidence","volume":"44","author":"Forough","year":"2021","journal-title":"Bull. Pharm. Sci., Assiut University"},{"key":"10.1016\/j.ejmech.2025.118213_bib216","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40267-013-0106-0","article-title":"Desloratadine: a guide to its use in allergic disorders","volume":"30","author":"Lyseng-Williamson","year":"2014","journal-title":"Drugs Ther. Perspect."},{"key":"10.1016\/j.ejmech.2025.118213_bib217","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41467-023-44477-4","article-title":"Molecular mechanism of antihistamines recognition and regulation of the histamine H1 receptor","volume":"15","author":"Wang","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118213_bib218","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/all.12531","article-title":"Update on rupatadine in the management of allergic disorders","volume":"70","author":"Mullol","year":"2015","journal-title":"Allergy"},{"key":"10.1016\/j.ejmech.2025.118213_bib219","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000112899","article-title":"Studies to assess if Pizotifen prophylaxis improves migraine beyond the Benefit offered by acute Sumatriptan therapy alone","volume":"38","author":"Cleland","year":"2007","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.ejmech.2025.118213_bib220","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2165\/00003495-199040030-00006","article-title":"Ketotifen","volume":"40","author":"Grant","year":"1990","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.118213_bib221","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3132\/pcrj.2008.00028","article-title":"Prolonged cough in children: a summary of the Belgian primary care clinical guideline, Prim","volume":"17","author":"Leconte","year":"2008","journal-title":"Care Respir. J."},{"key":"10.1016\/j.ejmech.2025.118213_bib222","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1248\/cpb.7.372","article-title":"A new potent non-narcotic antitussive, 1-Methyl-3-di (2-thienyl) methylenepiperidine. Pharmacology and clinical efficacy","volume":"7","author":"Kase","year":"1959","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.ejmech.2025.118213_bib223","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.2042-7158.1991.tb06676.x","article-title":"Inhibitory effects of non-narcotic antitussive drugs on Cholinergically and non-cholinergically mediated Neurogenic Contractions of Guinea-pig isolated bronchial muscle","volume":"43","author":"Kamikawa","year":"1991","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118213_bib224","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.bbr.2011.09.031","article-title":"Pharmacological mechanisms of antidepressant-like effect of tipepidine in the forced swimming test","volume":"226","author":"Kawaura","year":"2012","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.ejmech.2025.118213_bib225","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1177\/0004867414553952","article-title":"Old drug tipepidine as new hope for children with ADHD","volume":"49","author":"Hashimoto","year":"2015","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.ejmech.2025.118213_bib226","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13065-018-0511-5","article-title":"Therapeutic importance of synthetic thiophene","volume":"12","author":"Shah","year":"2018","journal-title":"Chem. Cent. J."},{"key":"10.1016\/j.ejmech.2025.118213_bib227","series-title":"Drug Discovery: A History","first-page":"127","author":"Sneader","year":"2005"},{"key":"10.1016\/j.ejmech.2025.118213_bib228","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10735-024-10341-y","article-title":"MiRNAs and tempol therapeutic potential in prostate cancer: a preclinical approach","volume":"56","author":"Rossetto","year":"2025","journal-title":"J. Mol. Histol."},{"key":"10.1016\/j.ejmech.2025.118213_bib229","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/acsomega.3c07624","article-title":"Antiproliferative and apoptotic effects of tempol, Methotrexate, and their combinations on the MCF7 breast cancer cell line","volume":"9","author":"Kaplan","year":"2024","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2025.118213_bib230","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.exer.2010.04.012","article-title":"Protection of retinal pigment epithelium by OT-551 and its metabolite TEMPOL-H against light-induced damage in rats","volume":"91","author":"Tanito","year":"2010","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.ejmech.2025.118213_bib231","doi-asserted-by":"crossref","first-page":"6131","DOI":"10.1167\/iovs.10-5637","article-title":"Treatment of Geographic atrophy by the topical administration of OT-551: results of a phase II clinical trial","volume":"51","author":"Wong","year":"2010","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejmech.2025.118213_bib232","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1213\/00000539-197011000-00016","article-title":"Studies with Myfadol, A new analgesic agent","volume":"49","author":"Shulman","year":"1970","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.ejmech.2025.118213_bib233","series-title":"Orally Administered Analgesic Composition Comprising Myfadol","author":"Shulman","year":"2001"},{"key":"10.1016\/j.ejmech.2025.118213_bib234","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejca.2015.12.023","article-title":"Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy","volume":"57","author":"Rapoport","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejmech.2025.118213_bib235","series-title":"NK1 Antagonists","author":"Paliwal","year":"2011"},{"key":"10.1016\/j.ejmech.2025.118213_bib236","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1039\/jr9520003587","article-title":"683. Solanum alkaloids. Part VIII. Solamargine, a new alkaloid from solanum marginatum","author":"Briggs","year":"1952","journal-title":"J. Chem. Soc."},{"key":"10.1016\/j.ejmech.2025.118213_bib237","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/ptr.5809","article-title":"Anticancer properties of Solamargine: a systematic review","volume":"31","author":"Kalalinia","year":"2017","journal-title":"Phytother Res."},{"key":"10.1016\/j.ejmech.2025.118213_bib238","series-title":"LTD, an Open-Label, Multiple-Dose, Pharmacokinetic Study of SR-T100 Gel (Containing 2.3% Solamargine in Solanum Undatum Plant Extract) in Patients with Actinic Keratosis","year":"2019"},{"key":"10.1016\/j.ejmech.2025.118213_bib239","year":"2008"},{"key":"10.1016\/j.ejmech.2025.118213_bib240","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jns.2006.05.039","article-title":"Budipine in Parkinson's tremor","volume":"248","author":"Reichmann","year":"2006","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.ejmech.2025.118213_bib241","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/00045391-200201000-00010","article-title":"Meperidine: a critical review","volume":"9","author":"Latta","year":"2002","journal-title":"Am. J. Ther."},{"key":"10.1016\/j.ejmech.2025.118213_bib242","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.2146\/ajhp060672","article-title":"Eradicating analgesic use of meperidine in a hospital","volume":"64","author":"Raymo","year":"2007","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.ejmech.2025.118213_bib243","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0022-3565(25)11805-3","article-title":"Pharmacology of ethyl-1-(4-aminophenethyl)-4-phenylisonipecotate, anileridine, a new potent synthetic analgesic","volume":"119","author":"Orahovats","year":"1957","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejmech.2025.118213_bib244","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1080\/00085030.2000.10757504","article-title":"Anileridine fatalities: an Update","volume":"33","author":"Singer","year":"2000","journal-title":"Can. Soc. Forensic Sci. J."},{"key":"10.1016\/j.ejmech.2025.118213_bib245","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0378-4274(84)90077-8","article-title":"Structure-toxicity relationship of aliphatic nitriles","volume":"22","author":"Hideji","year":"1984","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.ejmech.2025.118213_bib246","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1177\/030006057500300614","article-title":"A single-blind trial between Difenoxin and diphenoxylate: including observations of the action of Difenoxin on the liver Parenchyma","volume":"3","author":"Triandafillou","year":"1975","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.ejmech.2025.118213_bib247","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/0016-5085(80)90924-5","article-title":"Double-blind cross-over study comparing loperamide codeine and diphenoxylate in the treatment of chronic diarrhea","volume":"79","author":"Palmer","year":"1980","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejmech.2025.118213_bib248","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1039\/D1MD00239B","article-title":"Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from Mycobacterium tuberculosis to overcome kanamycin resistance","volume":"12","author":"Punetha","year":"2021","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib249","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1021\/acschemneuro.3c00455","article-title":"An engineered human-antibody fragment with fentanyl Pan-specificity that reverses carfentanil-induced respiratory depression","volume":"14","author":"Eubanks","year":"2023","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2025.118213_bib250","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/bja\/82.1.3","article-title":"Piritramide","volume":"82","author":"Kumar","year":"1999","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.ejmech.2025.118213_bib251","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1912770","article-title":"A phase 3 trial of Difelikefalin in hemodialysis patients with pruritus","volume":"382","author":"Fishbane","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118213_bib252","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s40265-024-01998-6","article-title":"Capivasertib: first approval","volume":"84","author":"Shirley","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.118213_bib253","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202211498","article-title":"Redesign of rifamycin antibiotics to overcome ADP-ribosylation-mediated resistance","volume":"61","author":"Lan","year":"2022","journal-title":"Angew. Chem., Int. Ed."},{"key":"10.1016\/j.ejmech.2025.118213_bib254","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005159.pub2","article-title":"Rifabutin for treating pulmonary tuberculosis","author":"Davies","year":"2007","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejmech.2025.118213_bib255","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2165\/00003495-199447060-00008","article-title":"Rifabutin","volume":"47","author":"Brogden","year":"1994","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.118213_bib256","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.cell.2005.07.014","article-title":"Allosteric modulation of the RNA polymerase catalytic reaction is an essential component of transcription control by rifamycins","volume":"122","author":"Artsimovitch","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.118213_bib257","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0006-2952(78)90233-2","article-title":"Spiperone: a ligand of choice for neuroleptic receptors: 1. Kinetics and characteristics of in vitro binding","volume":"27","author":"Leysen","year":"1978","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118213_bib258","doi-asserted-by":"crossref","first-page":"6442","DOI":"10.1038\/s41467-020-20221-0","article-title":"Structure of the dopamine D2 receptor in complex with the antipsychotic drug spiperone","volume":"11","author":"Im","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118213_bib259","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.trecan.2025.01.006","article-title":"Revumenib: a new era in acute leukemia treatment","volume":"11","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ejmech.2025.118213_bib260","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s40265-025-02161-5","article-title":"Revumenib: first approval","volume":"85","author":"Syed","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.118213_bib261","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s41586-023-05755-9","article-title":"MEN1 mutations mediate clinical resistance to menin inhibition","volume":"615","author":"Perner","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.118213_bib262","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1067\/mcp.2001.116514","article-title":"Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone\u2013insulin-like growth factor I axis in growth hormone\u2013deficient children","volume":"70","author":"Codner","year":"2001","journal-title":"Clin. Pharm. Therap."},{"key":"10.1016\/j.ejmech.2025.118213_bib263","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/jgh.15828","article-title":"Safety, pharmacokinetic, and pharmacodynamic study of sibofimloc, a novel FimH blocker in patients with active Crohn's disease","volume":"37","author":"Reinisch","year":"2022","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejmech.2025.118213_bib264","first-page":"80","article-title":"Ueber das Piperidin, ein neues Pflanzenalkaloid","volume":"29","author":"\u00d8rsted","year":"1820","journal-title":"Journal f\u00fcr Chemie und Physik"},{"key":"10.1016\/j.ejmech.2025.118213_bib265","doi-asserted-by":"crossref","DOI":"10.1016\/j.foodchem.2024.139980","article-title":"Preparation, pungency and bioactivity transduction of piperine from black pepper (Piper nigrum L.): a comprehensive review","volume":"456","author":"Zou","year":"2024","journal-title":"Food Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib266","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1002\/jssc.202000152","article-title":"Switchable-hydrophilicity solvent liquid-liquid microextraction versus dispersive liquid-liquid microextraction prior to HPLC-UV for the determination and isolation of piperine from Piper nigrum L","volume":"43","author":"Al-Nidawi","year":"2020","journal-title":"J. Sep. Sci."},{"key":"10.1016\/j.ejmech.2025.118213_bib267","first-page":"53","article-title":"Therapeutic potential of piperine: a comprehensive review","volume":"14","author":"Singh","year":"2024","journal-title":"Nat. Prod. J."},{"key":"10.1016\/j.ejmech.2025.118213_bib268","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.2217\/fmb-2023-0101","article-title":"Antibacterial and Immunological properties of piperine evidenced by preclinical studies: a systematic review","volume":"18","author":"Murase","year":"2023","journal-title":"Future Microbiol."},{"key":"10.1016\/j.ejmech.2025.118213_bib269","doi-asserted-by":"crossref","first-page":"5488","DOI":"10.3390\/cancers15225488","article-title":"The Promise of piperine in cancer chemoprevention","volume":"15","author":"Benayad","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2025.118213_bib270","first-page":"89","article-title":"Imbruvica (ibrutinib): first drug approved for the treatment of patients with waldenstr\u00f6m\u2019s macroglobulinemia","volume":"9","author":"Raedler","year":"2016","journal-title":"Am. Health Drug Benefits"},{"key":"10.1016\/j.ejmech.2025.118213_bib271","doi-asserted-by":"crossref","DOI":"10.1136\/bmjonc-2024-000418","article-title":"Recall of ibrutinib and issues with therapeutic approval","volume":"3","author":"Lipfert","year":"2024","journal-title":"BMJ Oncology"},{"key":"10.1016\/j.ejmech.2025.118213_bib272","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1124\/mol.116.107037","article-title":"Ability of Bruton's tyrosine kinase inhibitors to sequester Y551 and prevent phosphorylation determines potency for inhibition of Fc receptor but not B-cell receptor signaling","volume":"91","author":"Bender","year":"2017","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118213_bib273","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1130595","article-title":"Zanubrutinib for the treatment of lymphoid malignancies: current status and future directions","volume":"13","author":"Wolska-Washer","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2025.118213_bib274","doi-asserted-by":"crossref","DOI":"10.1177\/20406207221093980","article-title":"Zanubrutinib in lymphoproliferative disorders: a comprehensive review","volume":"13","author":"Mu\u00f1oz","year":"2022","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.ejmech.2025.118213_bib275","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116762","article-title":"Synthetic routes and clinical application of new drugs approved by EMA during 2023","volume":"277","author":"Xia","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib276","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116124","article-title":"Synthesis and clinical application of new drugs approved by FDA in 2023","volume":"265","author":"Wang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib277","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s40265-021-01643-6","article-title":"Avacopan: first approval","volume":"82","author":"Lee","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.118213_bib278","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1002\/jps.23495","article-title":"Pharmacokinetics and metabolism of SRX246: a potent and selective vasopressin 1a antagonist","volume":"102","author":"Fabio","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejmech.2025.118213_bib279","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40265-023-01983-5","article-title":"A neuroanatomic and pathophysiologic Framework for novel pharmacological approaches to the treatment of post-traumatic stress disorder","volume":"84","author":"Norred","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.118213_bib280","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2022.11.003","article-title":"FDA approval summary for lonafarnib (Zokinvy) for the treatment of Hutchinson-Gilford progeria syndrome and processing-deficient progeroid laminopathies","volume":"25","author":"Suzuki","year":"2023","journal-title":"Genet. Med."},{"key":"10.1016\/j.ejmech.2025.118213_bib281","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/s41467-024-45241-y","article-title":"Drug repurposing screen identifies lonafarnib as respiratory syncytial virus fusion protein inhibitor","volume":"15","author":"Sake","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118213_bib282","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1684\/ejd.2016.2839","article-title":"Rubber: new allergens and preventive measures","volume":"26","author":"Crepy","year":"2016","journal-title":"Eur. J. Dermatol."},{"key":"10.1016\/j.ejmech.2025.118213_bib283","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/DER.0000000000000648","article-title":"Positive Patch test reactions to Carba Mix and thiuram Mix: the North American contact Dermatitis group experience (1994\u20132016)","volume":"32","author":"Warshaw","year":"2021","journal-title":"Dermatitis"},{"key":"10.1016\/j.ejmech.2025.118213_bib284","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ijpharm.2018.01.046","article-title":"Trends in insect repellent formulations: a review","volume":"539","author":"Tavares","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejmech.2025.118213_bib285","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00018-016-2335-6","article-title":"The crystal structure of the AgamOBP1\u2022Icaridin complex reveals alternative binding modes and stereo-selective repellent recognition","volume":"74","author":"Drakou","year":"2017","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejmech.2025.118213_bib286","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1089\/cap.2022.0015","article-title":"Dose Proportionality and steady-state pharmacokinetics of Serdexmethylphenidate\/Dexmethylphenidate, a novel prodrug combination to treat attention-deficit\/hyperactivity disorder","volume":"32","author":"Braeckman","year":"2022","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.ejmech.2025.118213_bib287","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114898","article-title":"New drug approvals for 2021: synthesis and clinical applications","volume":"245","author":"Yuan","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib288","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.sleep.2023.05.001","article-title":"Safety and pharmacodynamics of a single infusion of danavorexton in adults with obstructive sleep apnea experiencing excessive daytime sleepiness despite adequate use of CPAP","volume":"107","author":"Bogan","year":"2023","journal-title":"Sleep Med."},{"key":"10.1016\/j.ejmech.2025.118213_bib289","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2207531119","article-title":"Orexin 2 receptor\u2013selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients","volume":"119","author":"Evans","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1016\/j.ejmech.2025.118213_bib290","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1038\/s41467-022-30601-3","article-title":"Molecular mechanism of the wake-promoting agent TAK-925","volume":"13","author":"Yin","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118213_bib291","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s40265-020-01301-3","article-title":"Rimegepant: first approval","volume":"80","author":"Scott","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.118213_bib292","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1007\/s10311-020-01022-9","article-title":"Passive and active targeting strategies for the delivery of the camptothecin anticancer drug: a review","volume":"18","author":"Behera","year":"2020","journal-title":"Environ. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118213_bib293","first-page":"737","article-title":"Irinotecan\u2014a case study for the transition from accelerated approval to traditional approval","volume":"34","author":"Mannix","year":"2000","journal-title":"Ther. Innov. Regul. Sci."},{"key":"10.1016\/j.ejmech.2025.118213_bib294","series-title":"Advances in Pharmacology","first-page":"103","article-title":"Chapter Four - clinical overview of NMDA-R antagonists and clinical practice","author":"Davoudian","year":"2020"},{"key":"10.1016\/j.ejmech.2025.118213_bib295","series-title":"Pharmaceutical Innovation: Revolutionizing Human Health","first-page":"211","article-title":"Chapter 2: discovery and developments of major drugs","author":"Landau","year":"1999"},{"key":"10.1016\/j.ejmech.2025.118213_bib296","first-page":"27","article-title":"New aspects of controlled release systems for local anaesthetics: a review, Trends Anaesth","volume":"9","author":"Rogobete","year":"2016","journal-title":"Crit. Care"},{"key":"10.1016\/j.ejmech.2025.118213_bib297","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1021\/acschemneuro.4c00782","article-title":"Synthesis and evaluation of benzylic 18F-labeled N-Biphenylalkynyl nipecotic acid derivatives for PET imaging of GABA transporter 1","volume":"16","author":"Knippenberg","year":"2025","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2025.118213_bib298","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114269","article-title":"Nipecotic acid as potential lead molecule for the development of GABA uptake inhibitors; structural insights and design strategies","volume":"234","author":"Singh","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib299","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.eplepsyres.2009.05.008","article-title":"Effects of \u03b3-aminobutyric acid (GABA) agonists and a GABA uptake inhibitor on pharmacoresistant seizure like events in organotypic hippocampal slice cultures","volume":"86","author":"Wahab","year":"2009","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.ejmech.2025.118213_bib300","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1038\/s41594-023-00983-z","article-title":"Molecular basis for substrate recognition and transport of human GABA transporter GAT1","volume":"30","author":"Zhu","year":"2023","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ejmech.2025.118213_bib301","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005612.pub3","article-title":"Tiagabine add\u2010on for drug\u2010resistant partial epilepsy","author":"Pulman","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejmech.2025.118213_bib302","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s40265-019-01225-7","article-title":"Lasmiditan: first approval","volume":"79","author":"Lamb","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.118213_bib303","year":"2022"},{"key":"10.1016\/j.ejmech.2025.118213_bib304","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/s41422-021-00527-4","article-title":"Structural basis for recognition of anti-migraine drug lasmiditan by the serotonin receptor 5-HT1F\u2013G protein complex","volume":"31","author":"Huang","year":"2021","journal-title":"Cell Res."},{"key":"10.1016\/j.ejmech.2025.118213_bib305","first-page":"193","volume":"7","author":"Omvik","year":"1993","journal-title":"Drug Ther."},{"key":"10.1016\/j.ejmech.2025.118213_bib306","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2165\/00003088-199120040-00002","article-title":"Clinical pharmacokinetics of ketanserin","volume":"20","author":"Persson","year":"1991","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2025.118213_bib307","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1177\/0897190014522063","article-title":"Alogliptin: safety, efficacy, and clinical implications","volume":"28","author":"Marino","year":"2015","journal-title":"J. Pharm. Pract."},{"key":"10.1016\/j.ejmech.2025.118213_bib308","first-page":"1059","article-title":"Linagliptin approved for type 2 diabetes","volume":"68","author":"Traynor","year":"2011","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.ejmech.2025.118213_bib309","author":"Nar"},{"key":"10.1016\/j.ejmech.2025.118213_bib310","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2165\/11632780-000000000-00000","article-title":"Safety and clinical pharmacokinetics of Nemonoxacin, a novel non-fluorinated quinolone, in Healthy Chinese volunteers following single and multiple oral doses","volume":"32","author":"Guo","year":"2012","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.ejmech.2025.118213_bib311","first-page":"445","article-title":"Evaluation of thenalidine tratrate (sandostene) in dermatological disorders","volume":"80","author":"Getzler","year":"1959","journal-title":"Can. Med. Assoc. J."},{"key":"10.1016\/j.ejmech.2025.118213_bib312","doi-asserted-by":"crossref","first-page":"10326","DOI":"10.1016\/j.bmc.2008.10.042","article-title":"Antimycobacterial and H1-antihistaminic activity of 2-substituted piperidine derivatives","volume":"16","author":"Weis","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib313","first-page":"522","article-title":"A fatal case of agranulocytosis due to thenalidine tartrate complicated by acute renal failure and mycelial abscesses of brain, scott","volume":"6","author":"Stevenson","year":"1961","journal-title":"Med. J."},{"key":"10.1016\/j.ejmech.2025.118213_bib314","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1046\/j.1365-2222.1999.00002.x","article-title":"Mizolastine: antihistaminic activity from preclinical data to clinical evaluation","volume":"29","author":"Simons","year":"1999","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.ejmech.2025.118213_bib315","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00403-019-01967-0","article-title":"Effects of combination of mizolastine and proteoglycan on chronic urticaria: a randomized controlled trial","volume":"311","author":"Xiong","year":"2019","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.ejmech.2025.118213_bib316","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1200\/JCO.23.01061","article-title":"Crenolanib and intensive chemotherapy in adults with newly diagnosed FLT3-mutated AML","volume":"42","author":"Wang","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.118213_bib317","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/s41467-018-08263-x","article-title":"Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms","volume":"10","author":"Zhang","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118213_bib318","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.1158\/1078-0432.CCR-12-0625","article-title":"Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors","volume":"18","author":"Heinrich","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118213_bib319","doi-asserted-by":"crossref","first-page":"eabq7839","DOI":"10.1126\/scitranslmed.abq7839","article-title":"An improved reporter identifies ruxolitinib as a potent and cardioprotective CaMKII inhibitor","volume":"15","author":"Reyes Gaido","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2025.118213_bib320","author":"Counago"},{"key":"10.1016\/j.ejmech.2025.118213_bib321","doi-asserted-by":"crossref","first-page":"31658","DOI":"10.1074\/jbc.R112.356485","article-title":"Calcium\/Calmodulin-dependent protein kinase kinase 2: roles in signaling and pathophysiology","volume":"287","author":"Racioppi","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib322","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(23)02196-7","article-title":"Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials","volume":"403","author":"Wagenlehner","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2025.118213_bib323","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1007\/s40121-023-00862-6","article-title":"Efficacy and safety of gepotidacin as treatment of uncomplicated urogenital Gonorrhea (EAGLE-1): design of a randomized, comparator-controlled, phase 3 study","volume":"12","author":"Perry","year":"2023","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.ejmech.2025.118213_bib324","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02245-17","article-title":"Cellular pharmacokinetics and intracellular activity of gepotidacin against Staphylococcus aureus isolates with different resistance phenotypes in models of Cultured phagocytic cells","volume":"62","author":"Peyrusson","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2025.118213_bib325","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1021\/acsinfecdis.8b00315","article-title":"Mechanistic and structural basis for the actions of the antibacterial gepotidacin against Staphylococcus aureus gyrase","volume":"5","author":"Gibson","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ejmech.2025.118213_bib326","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1634\/theoncologist.2014-0241","article-title":"FDA Approval Summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements","volume":"19","author":"Kazandjian","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.ejmech.2025.118213_bib327","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29602","article-title":"FDA approval summary: crizotinib for pediatric and young adult patients with relapsed or refractory systemic anaplastic large cell lymphoma","volume":"69","author":"Merino","year":"2022","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.ejmech.2025.118213_bib328","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature13194","article-title":"Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy","volume":"508","author":"Huber","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.118213_bib329","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1007\/s001150050521","article-title":"Leukopenie unter ButyrophenonenErfolgreiche Psychosebehandlung durch Neuroleptika-Intervallverabreichung","volume":"70","author":"Grube","year":"1999","journal-title":"Nervenarzt"},{"key":"10.1016\/j.ejmech.2025.118213_bib330","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001949.pub3","article-title":"Pimozide for schizophrenia or related psychoses","author":"Mothi","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejmech.2025.118213_bib331","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1542\/peds.79.6.1032","article-title":"Pimozide treatment of tic and Tourette disorders","volume":"79","author":"Shapiro","year":"1987","journal-title":"Pediatrics"},{"key":"10.1016\/j.ejmech.2025.118213_bib332","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsb.2023.107992","article-title":"Identification and evaluation of potential inhibitor molecules against TcyA from Candidatus Liberibacter asiaticus","volume":"215","author":"Lonare","year":"2023","journal-title":"J. Struct. Biol."},{"key":"10.1016\/j.ejmech.2025.118213_bib333","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1038\/s41467-022-29728-0","article-title":"Structure, gating, and pharmacology of human CaV3.3 channel","volume":"13","author":"He","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118213_bib334","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1111\/j.1572-0241.2007.01255.x","article-title":"Domperidone: review of pharmacology and clinical applications in gastroenterology","volume":"102","author":"Reddymasu","year":"2007","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.ejmech.2025.118213_bib335","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.1158\/1078-0432.CCR-16-1293","article-title":"FDA approval: alectinib for the treatment of metastatic, ALK-positive non\u2013small cell lung cancer following crizotinib","volume":"22","author":"Larkins","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118213_bib336","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s40265-017-0776-3","article-title":"Brigatinib: first global approval","volume":"77","author":"Markham","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.118213_bib337","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s40265-019-1062-3","article-title":"Gilteritinib: first global approval","volume":"79","author":"Dhillon","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.118213_bib338","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40265-014-0329-y","article-title":"Alectinib: a review of its use in advanced ALK-rearranged non-small cell lung cancer","volume":"75","author":"McKeage","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.118213_bib339","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s40262-023-01284-w","article-title":"Clinical pharmacology of brigatinib: a next-generation anaplastic lymphoma kinase inhibitor","volume":"62","author":"Gupta","year":"2023","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2025.118213_bib340","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/1120009X.2021.1937782","article-title":"Comparison of lorlatinib, alectinib and brigatinib in ALK inhibitor\u2013naive\/untreated ALK-positive advanced non-small-cell lung cancer: a systematic review and network meta-analysis","volume":"34","author":"Wang","year":"2022","journal-title":"J. Chemther."},{"key":"10.1016\/j.ejmech.2025.118213_bib341","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2022.106808","article-title":"Gilteritinib in the management of acute myeloid leukemia: current evidence and future directions","volume":"114","author":"Nuho\u011flu Kantarc\u0131","year":"2022","journal-title":"Leuk. Res."},{"key":"10.1016\/j.ejmech.2025.118213_bib342","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1080\/14737140.2018.1527688","article-title":"A comprehensive review of protein kinase inhibitors for cancer therapy","volume":"18","author":"Kannaiyan","year":"2018","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.ejmech.2025.118213_bib343","doi-asserted-by":"crossref","first-page":"4443","DOI":"10.1042\/BCJ20200735","article-title":"A-loop interactions in Mer tyrosine kinase give rise to inhibitors with two-step mechanism and long residence time of binding","volume":"477","author":"Pflug","year":"2020","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2025.118213_bib344","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nri2303","article-title":"Immunobiology of the TAM receptors","volume":"8","author":"Lemke","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejmech.2025.118213_bib345","doi-asserted-by":"crossref","first-page":"116","DOI":"10.2165\/00003495-199447010-00008","article-title":"Cisapride","volume":"47","author":"Wiseman","year":"1994","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.118213_bib346","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1056\/NEJM199607253350416","article-title":"Cisapride and fatal arrhythmia","volume":"335","author":"Wysowski","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118213_bib347","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2165\/00003495-198300251-00007","article-title":"Metoclopramide","volume":"25","author":"Gralla","year":"1983","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.118213_bib348","year":"1997"},{"key":"10.1016\/j.ejmech.2025.118213_bib349","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1080\/17512433.2019.1620104","article-title":"Use of prucalopride in adults with chronic idiopathic constipation","volume":"12","author":"Vijayvargiya","year":"2019","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118213_bib350","first-page":"289","article-title":"Extrapyramidal toxicity caused by metoclopramide and clebopride: study of voluntary notifications of adverse effects to the Spanish Drug Surveillance System","volume":"21","author":"Cuena Boy","year":"1998","journal-title":"Aten. Prim."},{"key":"10.1016\/j.ejmech.2025.118213_bib351","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(12)61845-5","article-title":"Lomitapide for homozygous familial hypercholesterolaemia","volume":"381","author":"Raal","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2025.118213_bib352","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2116\/xraystruct.25.83","article-title":"Crystal structure of fentanyl base","volume":"25","author":"Ogawa","year":"2009","journal-title":"X-Ray Struct. Anal. Online"},{"key":"10.1016\/j.ejmech.2025.118213_bib353","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41398-019-0625-0","article-title":"The rising crisis of illicit fentanyl use, overdose, and potential therapeutic strategies","volume":"9","author":"Han","year":"2019","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.ejmech.2025.118213_bib354","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.jpain.2014.08.010","article-title":"The fentanyl story","volume":"15","author":"Stanley","year":"2014","journal-title":"J. Pain"},{"key":"10.1016\/j.ejmech.2025.118213_bib355","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112049","article-title":"A trypanosome-derived immunotherapeutics platform elicits potent high-affinity antibodies, negating the effects of the synthetic opioid fentanyl","volume":"42","author":"Triller","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2025.118213_bib356","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1016\/j.cell.2022.09.041","article-title":"Molecular recognition of morphine and fentanyl by the human \u03bc-opioid receptor","volume":"185","author":"Zhuang","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.118213_bib357","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1021\/acschemneuro.3c00455","article-title":"An engineered human-antibody fragment with fentanyl pan-specificity that reverses carfentanil-induced respiratory depression","volume":"14","author":"Eubanks","year":"2023","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2025.118213_bib358","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.str.2022.11.008","article-title":"Structures of drug-specific monoclonal antibodies bound to opioids and nicotine reveal a common mode of binding","volume":"31","author":"Rodarte","year":"2023","journal-title":"Structure"},{"key":"10.1016\/j.ejmech.2025.118213_bib359","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112049","article-title":"A trypanosome-derived immunotherapeutics platform elicits potent high-affinity antibodies, negating the effects of the synthetic opioid fentanyl","volume":"42","author":"Triller","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2025.118213_bib360","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s40265-016-0597-9","article-title":"Pimavanserin: first global approval","volume":"76","author":"Markham","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.118213_bib361","doi-asserted-by":"crossref","first-page":"14478","DOI":"10.1021\/acs.jmedchem.4c01244","article-title":"Dual 5-ht2a and 5-HT2C receptor inverse agonist that affords in vivo antipsychotic efficacy with minimal hERG inhibition for the treatment of dementia-related psychosis","volume":"67","author":"Oguma","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib362","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1358\/dot.2019.55.9.3020160","article-title":"Glasdegib for the treatment of adult patients with newly diagnosedacute myeloid leukemia or high-grade myelodysplastic syndrome whoare elderly or otherwise unfit for standard induction chemotherapy","volume":"55","author":"Goldsmith","year":"2019","journal-title":"Drugs Today"},{"key":"10.1016\/j.ejmech.2025.118213_bib363","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40265-018-1047-7","article-title":"Glasdegib: first global approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.118213_bib364","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.bulcan.2020.09.006","article-title":"AMMs au niveau europ\u00e9en : glasdegib dans la leuc\u00e9mie aigu\u00eb my\u00e9lo\u00efde","volume":"107","author":"Barri\u00e8re","year":"2020","journal-title":"Bull. Du Cancer"},{"key":"10.1016\/j.ejmech.2025.118213_bib365","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0021-8707(56)90042-9","article-title":"Clinical evaluation of Diphenylpyraline","volume":"27","author":"Nachtigall","year":"1956","journal-title":"J. Allergy"},{"key":"10.1016\/j.ejmech.2025.118213_bib366","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/030006057700500106","article-title":"Diphenylpyraline (Lergobine\u00ae) in the treatment of patients suffering from allergic and vasomotor rhinitis","volume":"5","author":"Puhakka","year":"1977","journal-title":"Int. J. Med. Res."},{"key":"10.1016\/j.ejmech.2025.118213_bib367","doi-asserted-by":"crossref","first-page":"156","DOI":"10.18176\/jiaci.0401","article-title":"Ebastine in the treatment of allergic rhinitis and urticaria: 30 Years of clinical studies and real-world experience","volume":"30","author":"Sastre","year":"2020","journal-title":"J Investig. Allergol. Clin. Immunol."},{"key":"10.1016\/j.ejmech.2025.118213_bib368","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.2165\/11205880-000000000-00000","article-title":"Oral bepotastine","volume":"70","author":"Lyseng-Williamson","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.118213_bib369","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s40261-012-0046-9","volume":"33","author":"McKeage","year":"2013","journal-title":"Propiverine, Clin. Drug Investig."},{"key":"10.1016\/j.ejmech.2025.118213_bib370","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s40265-018-1036-x","article-title":"Revefenacin: first global approval","volume":"79","author":"Heo","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.118213_bib371","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.str.2024.05.011","article-title":"Protein engineering enables a soakable crystal form of human CDK7 primed for high-throughput crystallography and structure-based drug design","volume":"32","author":"Mukherjee","year":"2024","journal-title":"Structure"},{"key":"10.1016\/j.ejmech.2025.118213_bib372","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1038\/s41467-024-46375-9","article-title":"High-resolution cryo-EM of the human CDK-activating kinase for structure-based drug design","volume":"15","author":"Cushing","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118213_bib373","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.bpj.2020.12.030","article-title":"2.5 \u00c5-resolution structure of human CDK-activating kinase bound to the clinical inhibitor ICEC0942","volume":"120","author":"Greber","year":"2021","journal-title":"Biophys. J."},{"key":"10.1016\/j.ejmech.2025.118213_bib374","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/cmdc.201600535","article-title":"Inhibitor selectivity for cyclin-dependent kinase 7: a structural, thermodynamic, and modelling study","volume":"12","author":"Hazel","year":"2017","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2025.118213_bib375","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114282","article-title":"Recent results from non-basic glycosidase inhibitors: how structural diversity can inform general strategies for improving inhibition potency","volume":"235","author":"Simone","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib376","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s40265-016-0607-y","article-title":"Migalastat: first global approval","volume":"76","author":"Markham","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.118213_bib377","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jpba.2015.06.010","article-title":"Rapid determination of 1-deoxynojirimycin in Morus alba L. leaves by direct analysis in real time (DART) mass spectrometry","volume":"114","author":"Xu","year":"2015","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejmech.2025.118213_bib378","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1124\/mol.61.1.186","article-title":"The \u03b1-glucosidase inhibitor 1-deoxynojirimycin blocks human immunodeficiency virus envelope glycoprotein-mediated membrane fusion at the CXCR4 binding step","volume":"61","author":"Papandr\u00e9ou","year":"2002","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118213_bib379","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.tifs.2019.05.010","article-title":"1-Deoxynojirimycin, its potential for management of non-communicable metabolic diseases","volume":"89","author":"Thakur","year":"2019","journal-title":"Trends Food Sci. Technol."},{"key":"10.1016\/j.ejmech.2025.118213_bib380","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.bbrc.2006.03.111","article-title":"1-Deoxymannojirimycin, the \u03b11,2-mannosidase inhibitor, induced cellular endoplasmic reticulum stress in human hepatocarcinoma cell 7721","volume":"344","author":"Lu","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2025.118213_bib381","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/307755a0","article-title":"Novel mannosidase inhibitor blocking conversion of high mannose to complex oligosaccharides","volume":"307","author":"Fuhrmann","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.118213_bib382","doi-asserted-by":"crossref","first-page":"15586","DOI":"10.1074\/jbc.M111.223172","article-title":"Analysis of a new family of widely distributed metal-independent \u03b1-mannosidases provides unique insight into the processing of N-linked glycans","volume":"286","author":"Gregg","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib383","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1002\/cbic.201700080","article-title":"Conformational behaviour of azasugars based on mannuronic acid","volume":"18","author":"van Rijssel","year":"2017","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejmech.2025.118213_bib384","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1017\/erm.2024.34","article-title":"MAN2B1 in immune system-related diseases, neurodegenerative disorders and cancers: functions beyond \u03b1-mannosidosis","volume":"27","author":"Han","year":"2025","journal-title":"Expert Rev. Mol. Med."},{"key":"10.1016\/j.ejmech.2025.118213_bib385","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrd1014","article-title":"New drug approvals for 2002","volume":"2","author":"Frantz","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.118213_bib386","first-page":"294","article-title":"FDA new drug approvals in 2003","volume":"52","author":"Wynn","year":"2004","journal-title":"Gen. Dent."},{"key":"10.1016\/j.ejmech.2025.118213_bib387","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/ajh.20504","article-title":"Guidance on the use of miglustat for treating patients with type 1 Gaucher disease","volume":"80","author":"Weinreb","year":"2005","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ejmech.2025.118213_bib388","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s41687-024-00805-w","article-title":"Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe disease","volume":"8","author":"Kishnani","year":"2024","journal-title":"J. Patient-Rep. Outcomes"},{"key":"10.1016\/j.ejmech.2025.118213_bib389","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S1474-4422(21)00331-8","article-title":"Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial","volume":"20","author":"Schoser","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejmech.2025.118213_bib390","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/cpt.790","article-title":"Lucerastat, an iminosugar for substrate reduction therapy: tolerability, pharmacodynamics, and pharmacokinetics in patients with Fabry disease on enzyme replacement","volume":"103","author":"Gu\u00e9rard","year":"2018","journal-title":"Clin. Pharm. Therap."},{"key":"10.1016\/j.ejmech.2025.118213_bib391","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/jcph.1808","article-title":"Effect of renal function impairment on the pharmacokinetics, safety, and tolerability of the iminosugar Sinbaglustat","volume":"61","author":"Melchior","year":"2021","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118213_bib392","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/cts.12911","article-title":"Assessment of target engagement in a first-in-human trial with Sinbaglustat, an iminosugar to treat lysosomal storage disorders","volume":"14","author":"Gehin","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.ejmech.2025.118213_bib393","doi-asserted-by":"crossref","first-page":"521","DOI":"10.2165\/00003495-200059030-00012","article-title":"Miglitol","volume":"59","author":"Scott","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.118213_bib394","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12986-015-0048-8","article-title":"Review: miglitol has potential as a therapeutic drug against obesity","volume":"12","author":"Sugimoto","year":"2015","journal-title":"Nutr. Metab."},{"key":"10.1016\/j.ejmech.2025.118213_bib395","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1021\/bi9016457","article-title":"New glucosidase inhibitors from an ayurvedic herbal treatment for type 2 diabetes: structures and inhibition of human intestinal maltase-glucoamylase with compounds from salacia reticulata","volume":"49","author":"Sim","year":"2010","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2025.118213_bib396","author":"Tan"},{"key":"10.1016\/j.ejmech.2025.118213_bib397","series-title":"The Microbiota in Gastrointestinal Pathophysiology","first-page":"37","article-title":"Chapter 4 - identification of the microbiota in the aging process","author":"Sarkar","year":"2017"},{"key":"10.1016\/j.ejmech.2025.118213_bib398","doi-asserted-by":"crossref","first-page":"128","DOI":"10.2174\/0929867329666220729151500","article-title":"Sulfonamide moiety as \u201cmolecular chimera\u201d in the design of new drugs","volume":"30","author":"Culletta","year":"2023","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib399","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s12551-021-00795-9","article-title":"Sulfonamide drugs: structure, antibacterial property, toxicity, and biophysical interactions","volume":"13","author":"Ovung","year":"2021","journal-title":"Biophys. Rev."},{"key":"10.1016\/j.ejmech.2025.118213_bib400","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11882-018-0791-9","article-title":"Sulfonamide drug allergy","volume":"18","author":"Dorn","year":"2018","journal-title":"Curr. Allergy Asthma Rep."},{"key":"10.1016\/j.ejmech.2025.118213_bib401","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1081-1206(10)60415-2","article-title":"Allergies to sulfonamide antibiotics and sulfur-containing drugs","volume":"100","author":"Dibbern","year":"2008","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.ejmech.2025.118213_bib402","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0031-6989(74)80054-8","article-title":"Clinical evaluation of Tibric Acid (CP 18,524) a new hypolipidemic agent","volume":"6","author":"Sirtori","year":"1974","journal-title":"Pharmacol. Res. Commun."},{"key":"10.1016\/j.ejmech.2025.118213_bib403","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1161\/ATVBAHA.108.179689","article-title":"Fibrates, glitazones, and peroxisome proliferator\u2013activated receptors","volume":"30","author":"Lalloyer","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ejmech.2025.118213_bib404","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1124\/jpet.121.000634","article-title":"The small molecule BC-2059 inhibits wingless\/integrated (Wnt)-Dependent gene transcription in cancer through disruption of the transducin \u03b2-like 1-\u03b2-Catenin protein complex","volume":"378","author":"Soldi","year":"2021","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejmech.2025.118213_bib405","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/S0959-8049(22)00852-8","article-title":"53 (PB043) - the TBL1 inhibitor, Tegavivint, suppresses tumour growth and enhances T-cell infiltration in preclinical murine \u03b2-Catenin mutant hepatocellular carcinoma","volume":"174","author":"Drake","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejmech.2025.118213_bib406","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/jnci\/djz026","article-title":"Tegavivint and the \u03b2-catenin\/ALDH Axis in chemotherapy-resistant and metastatic osteosarcoma","volume":"111","author":"Nomura","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ejmech.2025.118213_bib407","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1021\/jm00227a023","article-title":"Sulfamylurea hypoglycemic agents. 6. High-potency derivatives","volume":"19","author":"Sarges","year":"1976","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib408","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/jhet.5570150408","article-title":"An improved synthesis of gliamilide\u00ae, a high-potency sulfamylurea hypoglycemic agent","volume":"15","author":"Kuhla","year":"1978","journal-title":"J. Heterocycl. Chem."},{"issue":"243","key":"10.1016\/j.ejmech.2025.118213_bib409","first-page":"228","article-title":"Early clinical evaluation of the sulfamyl- urea gliamilide","volume":"17","author":"Ryan","year":"1975","journal-title":"Clin. Pharm. Therap."},{"key":"10.1016\/j.ejmech.2025.118213_bib410","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1158\/1535-7163.MCT-06-0355","article-title":"In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials","volume":"5","author":"DePinto","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejmech.2025.118213_bib411","series-title":"IL-8 Receptor Antagonists","author":"Busch-Petersen","year":"2007"},{"key":"10.1016\/j.ejmech.2025.118213_bib412","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz163","article-title":"Efficacy and safety of danirixin (GSK1325756) Co-administered with standard-of-care antiviral (Oseltamivir): a phase 2b, global, randomized study of adults hospitalized with influenza","volume":"6","author":"Madan","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.ejmech.2025.118213_bib413","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01020-2018","article-title":"Effect of the CXCR2 antagonist danirixin on symptoms and health status in COPD","volume":"52","author":"Lazaar","year":"2018","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejmech.2025.118213_bib414","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02414-18","article-title":"A novel small molecule, ZY354, inhibits dental caries-associated oral biofilms","volume":"63","author":"Zhang","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2025.118213_bib415","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111593","article-title":"Phenylthiazoles with nitrogenous side chain: an approach to overcome molecular obesity","volume":"182","author":"Elsebaei","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib416","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1021\/jm401905m","article-title":"Discovery and characterization of potent thiazoles versus methicillin- and vancomycin-resistant Staphylococcus aureus","volume":"57","author":"Mohammad","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib417","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.bmcl.2011.12.130","article-title":"Hit to lead evaluation of 1,2,3-triazolo[4,5-b]pyridines as PIM kinase inhibitors","volume":"22","author":"Pastor","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118213_bib418","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejmech.2019.02.022","article-title":"Discovery of novel triazolo[4,3-b]pyridazin-3-yl-quinoline derivatives as PIM inhibitors","volume":"168","author":"Mart\u00ednez-Gonz\u00e1lez","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib419","doi-asserted-by":"crossref","first-page":"S317","DOI":"10.1016\/j.clml.2013.05.019","article-title":"Biological effects of the pim kinase inhibitor, SGI-1776, in multiple myeloma","volume":"13","author":"Cervantes-Gomez","year":"2013","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.ejmech.2025.118213_bib420","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2018.03.060","article-title":"Design, synthesis and antitubercular evaluation of benzothiazinones containing a piperidine moiety","volume":"151","author":"Lv","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib421","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115125","article-title":"SAR study of piperidine derivatives as inhibitors of 1,4-dihydroxy-2-naphthoate isoprenyltransferase (MenA) from Mycobacterium tuberculosis","volume":"249","author":"Berg","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib422","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117082","article-title":"Design, synthesis, and biological evaluation of novel highly potent FXR agonists bearing piperidine scaffold","volume":"282","author":"Wang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib423","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117178","article-title":"Design, synthesis, and biological evaluation of novel N-Benzyl piperidine derivatives as potent HDAC\/AChE inhibitors for Alzheimer's disease","volume":"80","author":"Qin","year":"2023","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib424","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202200351","article-title":"Sialic acid 4-N-piperazine and piperidine derivatives bind with high affinity to the P. mirabilis sialic acid sodium solute symporter","volume":"17","author":"Bozzola","year":"2022","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2025.118213_bib425","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1021\/acs.jmedchem.5b01635","article-title":"8-Substituted pyrido[3,4-d]pyrimidin-4(3H)-one derivatives as potent, cell permeable, KDM4 (JMJD2) and KDM5 (JARID1) histone lysine demethylase inhibitors","volume":"59","author":"Bavetsias","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib426","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ejmech.2019.05.041","article-title":"C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-ones: studies towards the identification of potent, cell penetrant Jumonji C domain containing histone lysine demethylase 4 subfamily (KDM4) inhibitors, compound profiling in cell-based target engagement assays","volume":"177","author":"Le Bihan","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib427","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112214","article-title":"Discovery of aryl-piperidine derivatives as potential antipsychotic agents using molecular hybridization strategy","volume":"193","author":"Zhu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib428","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1021\/ci400481p","article-title":"Molecular modeling of the 3D structure of 5-ht1ar: discovery of novel 5-ht1ar agonists via dynamic pharmacophore-based virtual screening","volume":"53","author":"Xu","year":"2013","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2025.118213_bib429","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105353","article-title":"Design, synthesis, and antiviral evaluation of novel piperidine-substituted arylpyrimidines as HIV-1 NNRTIs by exploring the hydrophobic channel of NNIBP","volume":"116","author":"Zhang","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib430","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202100735","article-title":"Synthesis of aminoethyl-substituted piperidine derivatives as \u03c31 receptor ligands with antiproliferative properties","volume":"17","author":"Holtschulte","year":"2022","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2025.118213_bib431","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/aps.2016.124","article-title":"Discovery, synthesis, biological evaluation and structure-based optimization of novel piperidine derivatives as acetylcholine-binding protein ligands","volume":"38","author":"Shen","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2025.118213_bib432","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejmech.2018.09.073","article-title":"Discovery, cocrystallization and biological evaluation of novel piperidine derivatives as high affinity Ls-AChBP ligands possessing \u03b17 nAChR activities","volume":"160","author":"Yang","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib433","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112330","article-title":"Synthesis and biological evaluation of novel quinoline-piperidine scaffolds as antiplasmodium agents","volume":"198","author":"Van de Walle","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib434","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112223","article-title":"N-benzyl 4,4-disubstituted piperidines as a potent class of influenza H1N1 virus inhibitors showing a novel mechanism of hemagglutinin fusion peptide interaction","volume":"194","author":"de Castro","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib435","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112774","article-title":"Design, synthesis and biological activities of piperidine-spirooxadiazole derivatives as \u03b17 nicotinic receptor antagonists","volume":"207","author":"Zhang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib436","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115215","article-title":"Novel spiro[chromanone-2,4\u2032-piperidine]-4-one derivatives as potential inhibitors of fatty acid synthesis in pathogens: design, synthesis, and biological evaluation","volume":"250","author":"Liu","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib437","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1080\/14756366.2022.2150763","article-title":"Spiro heterocycles bearing piperidine moiety as potential scaffold for antileishmanial activity: synthesis, biological evaluation, and in silico studies","volume":"38","author":"Mohamed","year":"2023","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib438","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.1016\/j.bmc.2018.03.014","article-title":"Design, synthesis and biological evaluation of novel spiro-pentacylamides as acetyl-CoA carboxylase inhibitors","volume":"26","author":"Wei","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib439","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1021\/jm201503u","article-title":"Maximizing lipophilic efficiency: the use of free-wilson analysis in the design of inhibitors of acetyl-CoA carboxylase","volume":"55","author":"Freeman-Cook","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib440","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105108","article-title":"Design, synthesis and biological evaluation of novel diazaspirodecanone derivatives containing piperidine-4-carboxamide as chitin synthase inhibitors and antifungal agents","volume":"114","author":"Ji","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib441","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejmech.2019.01.050","article-title":"Attachment of a 5-nitrofuroyl moiety to spirocyclic piperidines produces non-toxic nitrofurans that are efficacious in vitro against multidrug-resistant Mycobacterium tuberculosis","volume":"166","author":"Krasavin","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib442","series-title":"Mechanism of Action of Antibacterial Agents","first-page":"176","article-title":"Nitrofurans","author":"McCalla","year":"1979"},{"key":"10.1016\/j.ejmech.2025.118213_bib443","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1016\/j.bmcl.2018.08.010","article-title":"Discovery of novel spiro[chromane-2,4\u2032-piperidine] derivatives as potent and orally bioavailable G-protein-coupled receptor 119 agonists","volume":"28","author":"Koshizawa","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118213_bib444","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1021\/acs.jmedchem.4c01673","article-title":"Structure-based development of novel spiro-piperidine ASH1L inhibitors","volume":"68","author":"Huang","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib445","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-23152-6","article-title":"Discovery of first-in-class inhibitors of ASH1L histone methyltransferase with anti-leukemic activity","volume":"12","author":"Rogawski","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118213_bib446","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.bmc.2018.12.043","article-title":"Design, synthesis and identification of novel coumaperine derivatives for inhibition of human 5-LOX: antioxidant, pseudoperoxidase and docking studies","volume":"27","author":"Muthuraman","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib447","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2019.07.051","article-title":"Synthesis and biological evaluation of 4-(piperid-3-yl)amino substituted 6-pyridylquinazolines as potent PI3K\u03b4 inhibitors","volume":"27","author":"Feng","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib448","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117275","article-title":"Discovery of novel JQ1 derivatives as dual ferroptosis and apoptosis inducers for the treatment of triple-negative breast cancer","volume":"286","author":"Ding","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib449","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1021\/acsmedchemlett.7b00363","article-title":"Nonacidic chemotype possessing N-acylated piperidine moiety as potent farnesoid X receptor (FXR) antagonists","volume":"9","author":"Teno","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118213_bib450","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejmech.2018.02.072","article-title":"Synthesis, molecular modeling and evaluation of \u03b1-glucosidase inhibition activity of 3,4-dihydroxy piperidines","volume":"150","author":"Kasturi","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib451","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115534","article-title":"Tetrahydrobenzo[h]quinoline derivatives as a novel chemotype for dual antileishmanial-antimalarial activity graced with antitubercular activity: design, synthesis and biological evaluation","volume":"257","author":"Ibrahim","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib452","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115867","article-title":"Optimization of piperidine constructed peptidyl derivatives as proteasome inhibitors","volume":"29","author":"Zhao","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib453","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ejmech.2019.02.050","article-title":"Design, synthesis and docking study of novel picolinamide derivatives as anticancer agents and VEGFR-2 inhibitors","volume":"168","author":"Zeidan","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib454","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111964","article-title":"Synthesis and anti-cancer activity studies of dammarane-type triterpenoid derivatives","volume":"187","author":"Ma","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib455","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113450","article-title":"Design and evaluation of novel piperidine HIV-1 protease inhibitors with potency against DRV-resistant variants","volume":"220","author":"Zhu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib456","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1016\/j.bmc.2018.04.051","article-title":"Discovery of benzimidazole derivatives as orally active renin inhibitors: optimization of 3,5-disubstituted piperidine to improve pharmacokinetic profile","volume":"26","author":"Tokuhara","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib457","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1021\/acsmedchemlett.6b00251","article-title":"Discovery of TAK-272: a novel, potent, and orally active renin inhibitor","volume":"7","author":"Imaeda","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118213_bib458","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ejmech.2019.06.043","article-title":"Design, synthesis and biological evaluations of 2-amino-4-(1-piperidine) pyridine derivatives as novel anti crizotinib-resistant ALK\/ROS1 dual inhibitors","volume":"179","author":"Liu","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib459","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103456","article-title":"Design, synthesis and biological evaluation of 2-arylaminopyrimidine derivatives bearing 1,3,8-triazaspiro[4,5]decan-4-one or piperidine-3-carboxamide moiety as novel Type-I1\/2 ALK inhibitors","volume":"94","author":"Miao","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib460","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1002\/cmdc.202000183","article-title":"A dual inhibitor of DYRK1A and GSK3\u03b2 for \u03b2-cell proliferation: aminopyrazine derivative GNF4877","volume":"15","author":"Liu","year":"2020","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2025.118213_bib461","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1021\/acsinfecdis.1c00635","article-title":"Optimization of benzoxazinorifamycins to minimize hPXR activation for the treatment of tuberculosis and HIV coinfection","volume":"8","author":"Ashkar","year":"2022","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ejmech.2025.118213_bib462","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2019.105046","article-title":"Design, synthesis, biological evaluation and molecular docking study of arylcarboxamido piperidine and piperazine-based hydroxamates as potential HDAC8 inhibitors with promising anticancer activity","volume":"138","author":"Trivedi","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejmech.2025.118213_bib463","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/leu.2013.231","article-title":"Histone deacetylase 3 as a novel therapeutic target in multiple myeloma","volume":"28","author":"Minami","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2025.118213_bib464","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113896","article-title":"Discovery of a cinnamyl piperidine derivative as new neddylation inhibitor for gastric cancer treatment","volume":"226","author":"Wang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib465","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1021\/acs.jmedchem.8b01328","article-title":"Structure-based in silico screening identifies a potent ebolavirus inhibitor from a traditional Chinese medicine library","volume":"62","author":"Shaikh","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib466","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112595","article-title":"Development of coumarine derivatives as potent anti-filovirus entry inhibitors targeting viral glycoprotein","volume":"204","author":"Gao","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib467","doi-asserted-by":"crossref","first-page":"7264","DOI":"10.1021\/acs.jmedchem.9b00891","article-title":"Discovery of 3,4,6-trisubstituted piperidine derivatives as orally active, low hERG blocking Akt inhibitors via conformational restriction and structure-based design","volume":"62","author":"Dong","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib468","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1021\/acs.jmedchem.8b01635","article-title":"Phenotypic screening-based identification of 3,4-disubstituted piperidine derivatives as macrophage M2 polarization modulators: an opportunity for treating multiple sclerosis","volume":"62","author":"Weng","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib469","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.106119","article-title":"Design and synthesis of N-(1-(6-(substituted phenyl)-pyridazin-3-yl)-piperidine-3-yl)-amine derivatives as JMJD6 inhibitors","volume":"129","author":"Qian","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib470","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111864","article-title":"Indazolyl-substituted piperidin-4-yl-aminopyrimidines as HIV-1 NNRTIs: design, synthesis and biological activities","volume":"186","author":"Xiao","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib471","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2019.126746","article-title":"Synthesis and antibacterial evaluation of novel oxazolidinone derivatives containing a piperidinyl moiety","volume":"29","author":"Hou","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118213_bib472","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1128\/AAC.00887-08","article-title":"Mode of action of ranbezolid against Staphylococci and structural modeling studies of its interaction with Ribosomes","volume":"53","author":"Kalia","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2025.118213_bib473","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ijantimicag.2012.09.013","article-title":"Anti-anaerobic potential of ranbezolid: insight into its mechanism of action against Bacteroides fragilis","volume":"41","author":"Mathur","year":"2013","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejmech.2025.118213_bib474","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.ejmech.2014.07.066","article-title":"Structure and evaluation of antibacterial and antitubercular properties of new basic and heterocyclic 3-formylrifamycin SV derivatives obtained via \u2018click chemistry\u2019 approach","volume":"84","author":"Pyta","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib475","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejmech.2019.02.009","article-title":"Synthesis, docking and antibacterial studies of more potent amine and hydrazone rifamycin congeners than rifampicin","volume":"167","author":"Pyta","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib476","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112624","article-title":"Synthesis, structure and anticancer activity of new geldanamycin amine analogs containing C(17)- or C(20)- flexible and rigid arms as well as closed or open ansa-bridges","volume":"202","author":"Skrzypczak","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib477","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115783","article-title":"Discovery of a novel series of potent carbonic anhydrase inhibitors with selective affinity for \u03bc Opioid receptor for Safer and long-lasting analgesia","volume":"260","author":"Angeli","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib478","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1021\/acs.jmedchem.7b01765","article-title":"Discovery and preclinical development of IIIM-290, an orally active potent cyclin-dependent kinase inhibitor","volume":"61","author":"Bharate","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib479","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115533","article-title":"Orally bioavailable styryl derivative of rohitukine-N-oxide inhibits CDK9\/T1 and the growth of pancreatic cancer cells","volume":"258","author":"Bhurta","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib480","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s40265-021-01508-y","article-title":"Trilaciclib: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.118213_bib481","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s10557-021-07285-w","article-title":"Flavopiridol mitigates the progression of monocrotaline-induced pulmonary hypertension in rats by targeting cyclin-dependent kinase 9","volume":"37","author":"Jia","year":"2023","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.ejmech.2025.118213_bib482","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/1479-5876-10-161","article-title":"Molecular evidence for increased antitumor activity of gemcitabine in combination with a cyclin-dependent kinase inhibitor, P276-00 in pancreatic cancers","volume":"10","author":"Rathos","year":"2012","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ejmech.2025.118213_bib483","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114840","article-title":"From dopamine 4 to sigma 1: synthesis, SAR and biological characterization of a piperidine scaffold of \u03c31 modulators","volume":"244","author":"Tolentino","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib484","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106437","article-title":"Benzoxazole-appended piperidine derivatives as novel anticancer candidates against breast cancer","volume":"134","author":"AboulWafa","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib485","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/cbdd.13760","article-title":"Design, synthesis, and biological evaluation of piperidinyl-substituted [1,2,4]triazolo[1,5-a]pyrimidine derivatives as potential anti-HIV-1 agents with reduced cytotoxicity","volume":"97","author":"Huang","year":"2021","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2025.118213_bib486","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.ejmech.2015.01.042","article-title":"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches","volume":"92","author":"Huang","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib487","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115847","article-title":"Bisubstrate inhibitors of 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase: transition state analogs for high affinity binding","volume":"29","author":"Shi","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib488","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bmc.2011.11.032","article-title":"Bisubstrate analogue inhibitors of 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase: new design with improved properties","volume":"20","author":"Shi","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib489","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ejmech.2018.03.004","article-title":"Structure-guided design of potent and permeable inhibitors of MERS coronavirus 3CL protease that utilize a piperidine moiety as a novel design element","volume":"150","author":"Galasiti Kankanamalage","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib490","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1039\/C6QO00720A","article-title":"One-pot synthesis of N-heterocycles and enimino carbocycles by tandem dehydrative coupling\u2013reductive cyclization of halo-sec-amides and dehydrative cyclization of olefinic sec-amides","volume":"4","author":"Huang","year":"2017","journal-title":"Org. Chem. Front."},{"key":"10.1016\/j.ejmech.2025.118213_bib491","doi-asserted-by":"crossref","first-page":"6858","DOI":"10.1039\/C9CC03127H","article-title":"TMSOTf mediated \u20185\/6-endo-dig\u2019 reductive hydroamination for the stereoselective synthesis of pyrrolidine and piperidine derivatives","volume":"55","author":"Gharpure","year":"2019","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2025.118213_bib492","doi-asserted-by":"crossref","first-page":"5850","DOI":"10.1021\/acs.orglett.3c02115","article-title":"Total synthesis of pyrrolidine and piperidine natural products via TMSOTf-mediated \u201c5\/6-endo-dig\u201d reductive hydroamination of enynyl amines","volume":"25","author":"Gharpure","year":"2023","journal-title":"Org. Lett."},{"key":"10.1016\/j.ejmech.2025.118213_bib493","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1021\/acs.joc.7b03278","article-title":"Domino reaction of pyrrolidinium ylides: Michael addition\/[1,2]-stevens rearrangement","volume":"83","author":"Kowalkowska","year":"2018","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib494","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1007\/s00706-018-2187-x","article-title":"Stereoselective one-pot synthesis of polycyanosubstituted piperidines","volume":"149","author":"Vereshchagin","year":"2018","journal-title":"Monatsh. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib495","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1055\/a-2004-6031","article-title":"Copper-catalyzed radical cascade annulation for the preparation of difluorinated pyrrolidines and piperidines","volume":"55","author":"Marchese","year":"2023","journal-title":"Synthesis"},{"key":"10.1016\/j.ejmech.2025.118213_bib496","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1021\/acs.jmedchem.6b01691","article-title":"Difluoromethyl bioisostere: examining the \u201clipophilic hydrogen bond donor\u201d concept","volume":"60","author":"Zafrani","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib497","doi-asserted-by":"crossref","DOI":"10.1016\/j.tet.2019.130637","article-title":"Diversity-oriented synthesis of bioactive azaspirocycles","volume":"75","author":"Lepovitz","year":"2019","journal-title":"Tetrahedron"},{"key":"10.1016\/j.ejmech.2025.118213_bib498","doi-asserted-by":"crossref","DOI":"10.1016\/j.tetlet.2020.151777","article-title":"Facile entry to substituted 2-arylpiperidines via an aza-Sakurai reaction","volume":"61","author":"Goodnough","year":"2020","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.ejmech.2025.118213_bib499","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1039\/C9CC07820G","article-title":"Regio- and chemoselective synthesis of nitrogen-containing heterocycles via the oxidative cascade cyclization of unactivated 1,n-enynes","volume":"56","author":"Mutra","year":"2020","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2025.118213_bib500","doi-asserted-by":"crossref","first-page":"4928","DOI":"10.1021\/acs.joc.5b00277","article-title":"Access to spirocyclized oxindoles and indolenines via palladium-catalyzed cascade reactions of propargyl carbonates with 2-oxotryptamines and tryptamines","volume":"80","author":"Nibbs","year":"2015","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib501","series-title":"Anthropogenic Platinum-Group Element Emissions: Their Impact on Man and Environment","first-page":"245","article-title":"Toxicology of platinum, palladium, rhodium, and their compounds","author":"Gebel","year":"2000"},{"key":"10.1016\/j.ejmech.2025.118213_bib502","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1078\/1438-4639-00180","article-title":"Palladium \u2013 a review of exposure and effects to human health","volume":"205","author":"Kielhorn","year":"2002","journal-title":"Int. J. Hyg Environ. Health"},{"key":"10.1016\/j.ejmech.2025.118213_bib504","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1021\/acsmedchemlett.1c00638","article-title":"Pilot study to quantify palladium impurities in lead-like compounds following commonly used purification techniques","volume":"13","author":"Chatzopoulou","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118213_bib505","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1021\/acs.oprd.3c00210","article-title":"Palladium extraction following metal-catalyzed reactions: recent advances and applications in the pharmaceutical industry","volume":"27","author":"Economidou","year":"2023","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.ejmech.2025.118213_bib506","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1595\/205651316X693247","article-title":"Palladium impurity removal from active pharmaceutical ingredient process streams: a method for scale-up","volume":"60","author":"Phillips","year":"2016","journal-title":"Johns. Matthey Technol. Rev."},{"key":"10.1016\/j.ejmech.2025.118213_bib507","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1021\/acs.orglett.9b03988","article-title":"Gold-catalyzed intramolecular dearomatization reactions of indoles for the synthesis of spiroindolenines and spiroindolines","volume":"22","author":"Wu","year":"2020","journal-title":"Org. Lett."},{"key":"10.1016\/j.ejmech.2025.118213_bib508","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1002\/ejoc.202000034","article-title":"Highly Cumulated radical cascade reaction of aza-1,6-Enyenes: stereoselective synthesis of exo-methylene piperidines","volume":"2020","author":"Kamimura","year":"2020","journal-title":"Eur. J. Org. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib509","doi-asserted-by":"crossref","first-page":"7722","DOI":"10.1016\/j.tet.2016.04.078","article-title":"A radical cascade reaction of aza-1,6-enyne compounds using allyltributyltin","volume":"72","author":"Kamimura","year":"2016","journal-title":"Tetrahedron"},{"key":"10.1016\/j.ejmech.2025.118213_bib510","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1021\/acs.orglett.5b02858","article-title":"Access to Polyfunctionalized chiral piperidines through enantioselective addition\u2013Carbocyclization cascade reaction catalyzed by a rhodium(I)\u2013Diene complex","volume":"17","author":"Serpier","year":"2015","journal-title":"Org. Lett."},{"key":"10.1016\/j.ejmech.2025.118213_bib511","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1002\/adsc.201901500","article-title":"Chemodivergent preparation of various heterocycles via phase-transfer catalysis: enantioselective synthesis of functionalized piperidines","volume":"362","author":"Bertuzzi","year":"2020","journal-title":"Adv. Synth. Catal."},{"key":"10.1016\/j.ejmech.2025.118213_bib512","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1016\/j.tetlet.2012.07.097","article-title":"Organocatalyzed stereoselective construction of N-formylpiperidines via a Michael-aza-Henry-hemiaminalization reaction cascade","volume":"53","author":"Chawla","year":"2012","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.ejmech.2025.118213_bib513","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1002\/ejoc.201403607","article-title":"A cascade aza-Cope\/aza-Prins cyclization leading to piperidine derivatives","volume":"2015","author":"Nallasivam","year":"2015","journal-title":"Eur. J. Org. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib514","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1016\/j.tetlet.2015.02.042","article-title":"Diastereoselective total synthesis of piperidine alkaloids: (2R,5R)-5-hydroxyhomopipecolic acid and (2R,5R,8R)-5-hydroxysedamine","volume":"56","author":"Khobare","year":"2015","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.ejmech.2025.118213_bib515","doi-asserted-by":"crossref","first-page":"6226","DOI":"10.1021\/acs.orglett.5b03209","article-title":"Allylic azide rearrangement in tandem with Huisgen cycloaddition for stereoselective annulation: synthesis of C-glycosyl iminosugars","volume":"17","author":"Moynihan","year":"2015","journal-title":"Org. Lett."},{"key":"10.1016\/j.ejmech.2025.118213_bib516","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1039\/C5OB02573G","article-title":"Synthesis of polyhydroxylated pyrrolidines from sugar-derived bromonitriles through a cascade addition of allylmagnesium bromide\/cyclization\/reduction","volume":"14","author":"Malik","year":"2016","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2025.118213_bib517","doi-asserted-by":"crossref","first-page":"5231","DOI":"10.1002\/chem.201905599","article-title":"Solution conformations explain the chameleonic behaviour of macrocyclic drugs","volume":"26","author":"Danelius","year":"2020","journal-title":"Chem. Eur J."},{"key":"10.1016\/j.ejmech.2025.118213_bib518","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/cbdd.12478","article-title":"Antibiotic adjuvants: diverse strategies for controlling drug-resistant pathogens","volume":"85","author":"Gill","year":"2015","journal-title":"Chem. Biol. Drug Des."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342500978X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342500978X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T21:33:21Z","timestamp":1764624801000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S022352342500978X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":513,"alternative-id":["S022352342500978X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118213","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Piperidine-containing drugs and recently studied analogs \u2013 biological activity, mechanism of action and synthetic cascade access to their scaffolds","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118213","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118213"}}